<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Mark Goad on Medium]]></title>
        <description><![CDATA[Stories by Mark Goad on Medium]]></description>
        <link>https://medium.com/@markjgoad?source=rss-d9ca5d9d52a0------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*cYWCQxnF061n_O9moNR7KQ@2x.jpeg</url>
            <title>Stories by Mark Goad on Medium</title>
            <link>https://medium.com/@markjgoad?source=rss-d9ca5d9d52a0------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 14:26:04 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@markjgoad/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Evidence-Based Longevity]]></title>
            <link>https://medium.com/@markjgoad/evidence-based-longevity-3f043004ea3e?source=rss-d9ca5d9d52a0------2</link>
            <guid isPermaLink="false">https://medium.com/p/3f043004ea3e</guid>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[longevity]]></category>
            <category><![CDATA[healthcare-technology]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Mark Goad]]></dc:creator>
            <pubDate>Sat, 21 Jun 2025 21:26:26 GMT</pubDate>
            <atom:updated>2025-06-21T21:26:26.008Z</atom:updated>
            <content:encoded><![CDATA[<h3>A Research-Driven Framework for Extending Life</h3><p>Part 1 of 10: Introduction, Longevity Extension Framework &amp; Metabolic Health</p><h3>1.0 Introduction</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*79gj_UmcxPuKmEasZan_ow.png" /><figcaption>Framework to contextualize and prioritize longevity extension interventions</figcaption></figure><p>I first came across the term ‘Longevity’ in 2019 when a friend asked me if I had read <a href="https://www.linkedin.com/in/davidsinclairphd/">David Sinclair’s</a> “<a href="https://www.amazon.ca/Lifespan-Why-Age_and-Dont-Have/dp/1501191977">‘Lifespan. Why We Age and Why We Don’t Have to</a>”.</p><p>At first, I felt the topic was solely the domain of old rich dudes who wanted to live forever encased in a gelatinous slurry.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/240/0*Z-wLsjcuh0dM0NTr" /><figcaption>Futurama [TV Series] by Matt Groening (1999–2013)</figcaption></figure><p>What made it real for me was connecting the ideas back to my parents — who are both approaching their 80s. In the sea of online healthfluencers, what are the one or two things I should help them focus on? I honestly didn’t know how to answer that question — until now.</p><h3>1.1 Why should we care now?</h3><p>Canada’s healthcare system is at a breaking point. We spend nearly $400Bn per year — the highest of OECD after adjusting for the age of our population, yet we rank last or close to last on the ability to find a primary care physician, get care outside of working hours, or see a specialist (<a href="https://www.fraserinstitute.org/sites/default/files/comparing-performance-of-universal-health-care-countries-2023.pdf">source</a>).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/468/0*8AWrDPsAjgQbAzXR" /><figcaption>United Nations Data Portal, Population Division, Canada, 2022 (<a href="https://www.wikiwand.com/en/articles/Demographics_of_Canada">source</a>).</figcaption></figure><p>With a huge cohort of these rascal boomers approaching what we know is the last two decades of their expected lives (81.3 years in Canada,<a href="https://www150.statcan.gc.ca/n1/daily-quotidien/231127/dq231127b-eng.htm"> source</a>) I believe we’re still in the early innings of this subject’s popularity.</p><p>Given my personal interests of digital health, running, sobriety, etc. (which I obnoxiously share on social media), I find myself having weekly conversations on ‘longevity’ with friends, family, entrepreneurs &amp; investors.</p><p>While I had started to map a few scattered points &amp; ideas on the topic of longevity — I was left <strong>feeling uneasy without a cogent framework</strong> from which I could answer simple questions like: where should I start?</p><p>To solve my own problem — I built the ‘Longevity Extension Framework’ and wrote this article. Let’s dive in!</p><h3>1.2 ✨Artificial Intelligence Disclaimer✨</h3><p>I used AI tools extensively throughout this work, across the entire pipeline of the research process. This was explicitly a big driver for why I was excited to write again after 5 years off!</p><p>I intentionally tried to use all the popular tools: for brainstorming (Claude), researching (Perplexity), refining (ChatGPT), image generation (Grok), and citations (Scite).</p><p>If I was forced to only use one — it would be Perplexity by a mile — consistently more accurate &amp; useful given its native quick links out.</p><p>Having done both entirely manual and now AI-assisted writing — I’d say it saved 20–30% of the overall time. I can’t wait to see where we are in 3–5 years.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*V_WPYmI2OGRokF2d" /><figcaption>“o3 is the first model to pass the ARC-AGI benchmark, an incredibly challenging test designed by the Alignment Research Center to detect artificial general intelligence–level reasoning, problem-solving, and self-improvement capabilities” (<a href="https://news.lore.com/p/a-christmas-ai-breakthrough-openai-s-o3-passes-the-agi-benchmark">source</a>).</figcaption></figure><h3>1.3 — History of Longevity</h3><p>Before we dive into a framework, I think it’s helpful to step back and ask, “how did we get here” and “where is ‘here’ exactly”?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/468/0*0loxWrWqjejkUWtN" /><figcaption>Image <a href="https://commons.wikimedia.org/wiki/File:Life_expectancy_in_Canada.svg">source</a></figcaption></figure><p>Here = 81.3 years of average life expectancy for Canadians in 2024. But how did we get here?</p><h3>1.4 — Levers of Longevity 1900–2000</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*GuCWTLVSvt0tWZBQ" /><figcaption>Cato Institute, Our World in Data (<a href="https://www.weforum.org/stories/2020/05/worlds-rise-life-expectancy-medicine-health/">source</a>)</figcaption></figure><p>For most of human history, we weren’t expected to make it past the age of 30. “Nasty, brutish, and short” was how Hobbes famously described life in the “state of nature” (<a href="https://1000wordphilosophy.com/2021/07/14/hobbes-on-the-state-of-nature/#:~:text=%25d-,%E2%80%9Cnasty%2C%20brutish%2C%20and%20short%E2%80%9D:%20thomas%20hobbes%20on,brutish%2C%20and%20short.%E2%80%9D.">source</a>).</p><p><strong>Life expectancy has more than doubled over the past 200 years </strong>— largely due to the fall in infant mortality (by 90%!), the introduction of medical sanitization practices, and antibiotics, (The Changing Landscape of American Life Expectancy, 2013, <a href="https://www.hamiltonproject.org/assets/files/changing_landscape_american_life_expectancy.pdf">source</a>). In the year 1900, diseases of infection killed 34% of us, today, that figure is 2%.</p><h3>1.5 — Pace of increasing Life Expectancy</h3><p>From the years 0–1990, we increased life expectancy by ONLY 1 year every century (100 years).</p><p>From the years 1900–2000, we increased life expectancy by 3 years every decade (10 years) (<a href="https://www.nature.com/articles/s43587-024-00702-3">source</a>).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/468/0*S0iIdeigntGcB2AA" /><figcaption>Image <a href="https://www.nature.com/articles/s43587-024-00702-3">source</a></figcaption></figure><p>If that sentence hurt your head (like mine) — here it is written out:</p><ul><li>Per year — increase of life expectancy (0–1900) = +0.01/year</li><li>Per year — increase of life expectancy (1900–2010) = +0.3/year</li><li>Change = 30x increase! (wow meme)</li></ul><p>Interestingly, our current rate of increase of life expectancy (+0.3 additional years of life expectancy gained per year) has started to decline to +0.2 additional years of life expectancy gained per year in every developed nation measured in the study except Hong Kong and South Korea, hence the tailing off of our progress in the first orange chart.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*weYDZ1L5KBfQdTI5" /><figcaption>Image <a href="https://www.nature.com/articles/s43587-024-00702-3#Sec2">source</a></figcaption></figure><h4>1.5.1 Longevity Escape Velocity (‘LEV’)</h4><p>LEV is the idea that the per year increase in life expectancy will eventually be greater than 1, meaning that your life will extend faster than the passage of time and <strong>you’ll theoretically live forever</strong>.</p><p>Several prominent ‘thinkfluencers’ have guessed we’ll hit this between 2030 and 2040, despite the fact that we’ve seen a marginal decline in the rate of increase in the past decade, noted above.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/960/0*4nYXgAYhDljXd55F" /><figcaption>Life trajectories according to when longevity escape velocity is reached (Image <a href="https://www.gowinglife.com/can-you-live-forever-part-1-why-exceptional-longevity-is-closer-than-you-think/">source</a>)</figcaption></figure><h4>1.5.2 Maximum Lifespan Theory</h4><p>There’s also about whether there is actually a maximum biological limit to human longevity (interesting read from 2019, <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7243589/#:~:text=The%20topic%20of%20the%20limit,%2Dspan%20limit%20(3).">source</a>).</p><p>Some scientists say yes, others say no — but we still don’t really know.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/630/0*qkLOwUulZXRaJl-v" /><figcaption>Image <a href="https://www.scientificamerican.com/article/humans-may-have-already-reached-their-maximum-lifespan/">source</a></figcaption></figure><h3>1.6 — Death Today</h3><p>Today, you’re much more likely to be killed by a horse than by an infection, according to Dr. Peter Attia (<a href="https://www.youtube.com/watch?v=dQw4w9WgXcQ">source</a>).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/468/0*PfA6fi_cGdjv_M9u" /><figcaption>Image Prompt: “Draw me a ‘death horse’ with a henchman with the face of Dr. Peter Attia for my article on longevity”, Grok 2.</figcaption></figure><p>Sorry — I meant one of the ‘four horsemen’.</p><p>In his expansive ‘<a href="https://www.amazon.ca/Outlive-Science-Art-Longevity/dp/5194152388/ref=asc_df_5194152388?mcid=6533d3228a42320d96af87345dcd70cc&amp;tag=googleshopc0c-20&amp;linkCode=df0&amp;hvadid=706839955142&amp;hvpos=&amp;hvnetw=g&amp;hvrand=11236010140089187936&amp;hvpone=&amp;hvptwo=&amp;hvqmt=&amp;hvdev=c&amp;hvdvcmdl=&amp;hvlocint=&amp;hvlocphy=9000945&amp;hvtargid=pla-2253646841964&amp;psc=1&amp;hvocijid=11236010140089187936-5194152388-&amp;hvexpln=0&amp;gad_source=1">Outlive. The Science &amp; Art of Longevity</a>’, Dr. Attia covers the shift from death by infection to death by chronic disease as I have above (though not as succinctly as I did, you’re welcome). These four chronic conditions claim the lives of over 80% of deaths in non-smoking individuals over 50 years old:</p><ol><li>Heart disease (atherosclerotic cardiovascular disease)</li><li>Cancer</li><li>Neurodegenerative disease (primarily Alzheimer’s disease)</li><li>Type 2 diabetes and related metabolic dysfunction</li></ol><p>Honestly, I’m just struck by how little we know about #2 and #3.</p><p>In general, the items listed in my proposed Longevity Framework below mechanistically address or diagnostically identify these diseases (or their precursors). The precise mechanism isn’t always 100% understood or perfectly attributable in a way that will satisfy all. We do know that the behavioral changes in Tier 1 help ward off at least one of the four horsemen above.</p><h3>2.0 — Longevity Extension Framework</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*79gj_UmcxPuKmEasZan_ow.png" /><figcaption>Image Prompt: ±60hrs of reading academic papers and organizing thoughts in endless Google Docs &amp; Apple Notes, by Mark.ai</figcaption></figure><h3>2.1 — Longevity Extension Framework: Years Added</h3><p>Let’s get ahead of this.</p><p>I find hazard ratios and mortality rates too abstract for the average person (me) to wrap my mind around. I used Deep Research a few times to translate hazard ratios to “years added” and look at how complicated this is → <a href="https://www.perplexity.ai/search/explain-the-following-in-numbe-EgYEDRktTy2c72oaTda8qQ">source</a>.</p><p>I instead chose to use the ‘<strong>years of life expectancy added</strong>’ framing for each intervention.</p><p>There’s some vaguely interesting research on how if we use this methodology, some healthy things will be ignored because ‘you only gain a week/month’ but since we’re focusing on the big blocks — let’s ignore that critique (<a href="https://www.nejm.org/doi/10.1056/NEJM199808063390606?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov#t01">source</a>).</p><h3>2.2 — Longevity Extension Framework: Study Selection Philosophy</h3><p>I had to pick which research studies to include and which to discard. My study selection philosophy was to prioritize large, recent, clear, and normalized studies.</p><p><strong>Large</strong>. I try to state the sample size of the study (‘n =’) and opt for larger/meta-studies where available (helping mitigate the effects of the <a href="https://en.wikipedia.org/wiki/Replication_crisis">replication crisis</a>).</p><p><strong>Recent</strong>. The more recent the study, the more applicable it is to our rapidly evolving social, food &amp; cultural paradigms that influence our health.</p><p><strong>Clear</strong>. I also try to pick studies where the degree of severity or intensity of the mechanism involved is super easy to understand (i.e., a regular drinker is defined as 3 drinks per week).</p><p><strong>Normalized</strong>. Last, I tried to standardize the effect size (i.e., number of years added), around a 30-year-old male for simplicity. If you’re interested, most of the studies provide various effect sizes for different population groups.</p><p>Even with this abundance of caution and context it’s important to acknowledge this framework is hardly MECE and my former managers from consulting are squirming in their tasseled loafers. I’d argue that anything meaningful in health related to longevity will necessarily not be MECE — we truly don’t have the ability to precisely segment and quantify behavioral attribution to health outcomes in a MECE compliant way. Stress, relationships, &amp; sleep being separate subcategories should be a tip here.</p><p>In spite of this — I think the framework makes sense and perhaps more importantly, is 1) easy to understand and 2) directionally (not precisely) correct.</p><h3>2.3 — Longevity Extension Framework: Where to start?</h3><p>‘Start by shooting the alligators closest to the boat’</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/410/0*DCuK3e7Djs-AfULB" /><figcaption>Image Prompt: “cartoon of Layne Norton on a boat in the amazon shooting alligators who are attacking him”, Grok 2.</figcaption></figure><p>I love this quote. It came during a conversation with Dr. Layne Norton on Andrew Huberman’s wildly successful podcast in a discussion of health &amp; longevity (<a href="https://www.youtube.com/watch?v=K4Ze-Sp6aUE">source</a>). I truly believe this is the right framing.</p><p>We should prioritize our limited energy and focus on the ‘biggest blocks’ in the framework in Tier 1, before moving up the ladder of the framework. They also happen to be the things you can largely control &amp; are usually ‘free’ or of little cost compared to the upper tiers.</p><p>My perspective is that only when you have a handle on these five tier 1 blocks should you start moving up the framework to the second and third tiers.</p><h3>3.1 — Tier 1: Behavioral — Metabolic Health</h3><p><strong>Subcategory:</strong> Obesity</p><p><strong>Indicator:</strong> Body Mass Index (‘BMI’)</p><p><strong>Added Life Expectancy:</strong> +9.7 years</p><ul><li>Average life expectancy effect of BMI of 40–60 vs. 20–30 BMI (n = 315k; 2014;<a href="https://pubmed.ncbi.nlm.nih.gov/25003901/"> source</a>)</li></ul><p>—</p><p>Pause</p><p>Before starting — I’m going to very intentionally take a moment to highlight some ‘body-positive’ content. We can &amp; must hold two ideas simultaneously: it’s OK to love your body &amp; want to improve because there is good evidence losing some weight will help you live longer &amp; happier. Here are some great videos to watch as a ‘pallet cleanser’ ft. Joey Swoll (CEO of Gym Positivity <a href="https://www.instagram.com/joeyswoll/reel/C4d5WOCP0IQ/">— his videos are great!</a>)</p><p>OK — let’s dive in.</p><p>–</p><h3>3.1 — Key Chart to remember</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*7p9mHyR4yNagvd2j" /><figcaption>Association of BMI with mortality (<a href="https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2818%2930288-2/fulltext">source</a>)</figcaption></figure><h4>3.1.1 Description of Longevity Mechanism</h4><ul><li>At +9.7 years, managing obesity is one of the largest drivers of additional years lived in the entire framework.</li><li>The disease impacts longevity in the following ways:</li></ul><h4><strong>3.1.1.1 Obesity &amp; Cardiovascular Disease</strong></h4><ul><li>Obesity is a major risk factor driving heart disease and stroke. Up to one in three deaths from heart attacks or strokes in the U.S. are linked to being overweight or obese (n = 900k, 2009,<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140673609603184/fulltext"> source</a>).</li></ul><h4>3.1.1.2 Obesity &amp; Cancer:</h4><ul><li>Obesity is a risk factor driving higher rates of certain cancers. The mechanisms behind this link are complex, but obesity-related inflammation and metabolic changes are believed to play significant roles (n = 23k, 2018,<a href="https://pubmed.ncbi.nlm.nih.gov/29178569/"> source</a>).</li></ul><h4>3.1.1.3 Obesity &amp; Diabetes</h4><ul><li>Obesity is closely tied to type 2 diabetes, hypertension, and other metabolic disorders, which can lead to serious complications and premature death. Individuals with severe obesity (BMI of 40 or higher) face a dramatically increased risk of these conditions (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3096264/">source</a> and<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6716964/"> source</a>).</li></ul><h4>3.1.1.4 Obesity &amp; Liver and Kidney Disease</h4><ul><li>Obesity can lead to non-alcoholic fatty liver disease and kidney disease, both of which are serious health issues that can shorten lifespan (n = 9161, 2024,<a href="https://www.nature.com/articles/s41598-024-63386-0"> source</a>).</li></ul><h3>3.1.2 Key Research Concepts &amp; Takeaways</h3><h4>3.1.2.1 ‘J-Curve’ relationship between BMI and Mortality</h4><p>A meta-analysis demonstrated that individuals with both underweight (BMI &lt; 18.5) and obesity (BMI &gt; 30) had higher mortality rates compared to those with a BMI between 22–27 (n =113k, 2021,<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8250762/"> source</a>)</p><h4>3.1.2.2 Diet matters less than calories</h4><p><strong>Calorie restriction &gt; specific diets</strong>. A 12-month randomized clinical trial comparing low-fat and low-carbohydrate diets found that both diets resulted in similar weight loss when calorie intake was normalized (n = 609, 2018,<a href="https://jamanetwork.com/journals/jama/fullarticle/2673150"> source</a>)</p><p><strong>Not all calories are the same — go for Protein</strong>. It’s better to optimize for high protein diets, with protein having a higher satiety factor (protein greatly increase levels of GLP-1s which we discuss below lead to feeling full) and diet-induced thermogenesis (meaning it takes more energy/calories to break them down) which is one of the three ways you burn calories. The other two ways you burn calories are activity-induced thermogenesis (exercise) and basal metabolic rate (energy used to keep you alive: heart beating, temperature regulation, etc.) (<a href="https://www.cfp.ca/content/cfp/66/2/117.full.pdf">source</a>). Proteins have a higher thermic effect (25–30%) compared to carbohydrates (6–8%) and fats (2–3%) (<a href="https://rnd.edpsciences.org/articles/rnd/abs/1996/04/RND_0926-5287_1996_36_4_ART0005/RND_0926-5287_1996_36_4_ART0005.html">source</a>).</p><h4>3.1.2.3 Clinical Studies of Popular Diets</h4><p><strong>Fasting</strong>. Only really works because of calorie constriction, not because of timing. “Compared with calorie restriction alone, fasting plus calorie restriction exhibited no significant benefit on the blood pressure, glucose profile, and lipid profile.” (n = 579, 2023,<a href="https://www.nature.com/articles/s41430-023-01311-w"> source</a>)</p><p><strong>Carnivore</strong>. The only study I could find on the carnivore diet didn’t have a control, was all self-reported (eye roll), and generally finds what other elimination diets find: if you can eat less things (i.e., only meat, no carbs, etc.) you’ll lose weight (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8684475/">source</a>). This group reported a median BMI reduction from 27.2 (already healthy) to 24.3.</p><h3>3.1.3 Mitigation via Tech, Pharma, LLMs &amp; Health Services</h3><h4>3.1.3.1 Pharma: GLP-1 Overview</h4><p>GLP-1s were the hottest healthcare topic in 2024 (beside longevity) and I’ve heard MANY claims about how they impact longevity — so I wanted to dive deeper.</p><h4><em>3.1.3.1.1 What the Heck is a GLP-1/Semaglutide?</em></h4><p>Your body naturally creates the chemical (technically it’s a ‘peptide hormone’) known as a GLP-1s in your gut today, in response to food intake (<a href="https://www.tinyhealth.com/blog/increase-glp-1-naturally">source</a>).</p><p>If you want to feel fuller and more satiated — it turns out you can take artificial GLP-1s (called semaglutide) and your body will react like you’ve eaten food. The brand names of semaglutide are Ozempic, Wegovy, and Rybelsus.</p><p>Semaglutide is a receptor ‘agonist’ that mimics GLP-1, meaning it is a chemical that activates the GLP-1 receptors on cells in our gastrointestinal tract, pancreas and brain (source = Perplexity +<a href="https://www.ncbi.nlm.nih.gov/books/NBK603723/"> here</a>). When it binds to our cells, semaglutide does the following things in the following places:</p><p>1) in your <strong>gastrointestinal tract:</strong> slows stomach emptying — meaning you’ll feel fuller; and</p><p>2) in your <strong>pancreas:</strong> triggers the release of insulin — reducing our blood sugar levels;</p><p>3) in your <strong>brain:</strong> binds to GLP-1 receptors in our hypothalamus, the part of the brain that regulates appetite, to help further reduce hunger.</p><p>Semaglutide was approved in 2017 as a treatment for type 2 diabetes for achieving up to a 1.9% reduction in A1C vs. a placebo in random control trials (n = 632, 2017,<a href="https://jamanetwork.com/journals/jama/fullarticle/2657376"> source</a>).</p><h4><em>3.1.3.1.2 Subsequent GLP-1 Studies</em></h4><p>Research has showed additional longevity &amp; health benefits to GLP-1s, including:</p><ul><li>15% body weight reduction (n = 304, 2019,<a href="https://www.nature.com/articles/s41591-022-02026-4"> source</a>) with weight loss effects maintained for up to four years (n = 17,604 [without diabetes], 2019,<a href="https://www.nature.com/articles/s41591-024-02996-7"> source</a>)</li><li>20% reduction in major adverse cardiovascular events (n = 17,604 [without diabetes], 2024,<a href="https://www.nature.com/articles/s41591-024-02996-7"> source</a>)</li><li>24% reduction in risk of kidney disease-related events (n = 3,533, 2024,<a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167028"> source</a>)</li><li>50% reduction in both the incidence and recurrence of alcohol use disorder (n = 83k, 2024,<a href="https://www.nature.com/articles/s41467-024-48780-6"> source</a>)</li><li>63% reduction in sleep apnea severity (n = [not given], 2024,<a href="https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-sleep-apnea-severity-nearly-two-thirds"> source</a>)</li><li>‘Significant’ improvements in non-alcoholic fatty liver disease (n = 2413, 2023,<a href="https://pubmed.ncbi.nlm.nih.gov/37717295/"> source</a>)</li><li>‘Significantly’ lower risk for tobacco use disorder (n = 223k, 2023,<a href="https://www.acpjournals.org/doi/10.7326/M23-2718"> source</a>)</li><li>‘Significantly’ lower risk for cannabis use disorder (n = 85k, 2024,<a href="https://www.nature.com/articles/s41380-024-02498-5"> source</a>)</li></ul><p>There’s anecdotal evidence that semaglutide reduced patient’s gambling and drug-use (including opioids, a huge problem in North America). These reports have kicked off some studies but there are no results to report, yet (<a href="https://www.scientificamerican.com/article/could-new-weight-loss-drugs-like-ozempic-treat-addiction1/">source</a>).</p><p>Perhaps <strong><em>counterintuitively</em></strong>, it’s clear that weight reduction is not the only mechanism at play.</p><p>“The starting weight or degree of weight loss when taking semaglutide <strong>doesn’t necessarily correlate with the level of mortality risk reduction</strong>, meaning even people who lose little to no weight on semaglutide may still see a <strong>reduction in cardiovascular death</strong>” and it’s not entirely clear why (n = 18k, 2024,<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01498-3/fulltext"> source</a>).</p><p>It’s clear there’s a lot of interest in using semaglutide to combat many of the chronic diseases we face today and investing more in researching its ‘off label’ impacts on key longevity drivers.</p><h4>3.1.3.2 Tech: Enterprise Market for Obesity Mitigation</h4><p>The major players in employer-focused metabolic digital health are:</p><ul><li>Noom (big D2C as well) founded in 2008</li><li>Livongo founded in 2008 (relaunched in 2014)</li><li>Virta Health founded in 2013</li><li>Omada Health founded in 2011</li><li>Lark Health founded in 2011</li></ul><p>Most of the recent innovation in the space has come on the back of GLP-1s, see WeightWatchers buying Sequence Health for $132M in 2023 (after it was founded in 2021). I excpect to see some AI-focused plays here (explored below).</p><p>Shoutout to my former team @ Curv Health — back in 2022, we were the first group in Canada to build &amp; sell a ‘Weight Management’ digital health exercise &amp; coaching program for a top-5 Canadian carrier to package alongside it’s GLP-1 offer.</p><h3>3.1.3.3 Tech: Consumer Market for Obesity Mitigation</h3><h4><em>3.1.3.3.1 Manual vs. Automated Data Collection in Digital Health</em></h4><p>During one of my first digital health investment pitches as a VC we talked about user friction in healthcare patient flows. If everyone wrote down everything they were eating, thinking and lifting — healthcare would be easy. We were trying to find startups that were using technology to ‘passively’ collect to assess &amp; mediate patient action.</p><p>I recall us looking at a company that claimed to be able to diagnose depression or ADHD just from tracking a user’s scrolling on their phone screen — requiring no specific patient action. That feels like the panacea for digital health. I don’t get overly excited about health apps that require constant and active user actions to be functional. I’m excited to see what happens as Meta continues to bring down the cost of their smart glasses and what that does for applications based on computer vision data capture.</p><h4><em>3.1.3.3.2 Computer Vision in Food Tracking</em></h4><p>We looked at this use case at Curv, using computer vision models to analyze what was on your plate and give you a caloric readout. It was REALLY hard to tell what was under the curry sauce (chicken vs. tofu) and what the portion sizing was, as monocular computer vision models are good at relative, not absolute sizing.</p><p>It appears these new models are much better at dealing with ambiguity (check out<a href="https://www.snapcalorie.com/"> SnapCalorie</a>,<a href="https://techcrunch.com/2023/06/26/snapcalorie-computer-vision-health-app-raises-3m/?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cudWx0cmFseXRpY3MuY29tLw&amp;guce_referrer_sig=AQAAABFl4w4VvUdgtnUxNgpy8qddY165Yadp0xTcnoozSA3jfNVvX7_ILT3tQM6jOX1vy9Ss_VrX9LVQFK4MMqXyXrN_R3uzvdZBGsoCo1PhFcgc5B2Pxu8XGv_5O9Fj8XZCET2EHRaJk_5Srva9BYsCOMo_0s9N5ZpBbLx5vo3eznTU"> backed by Accel, Index</a> + others in 2023) but I still think it’s too much friction, though they’ll be well positioned when we all eventually stick cameras on our faces (via glasses).</p><h4><em>3.1.3.3.3 LLMs or ‘LLyuMmmmmmms’ (I’m sorry)</em></h4><p>LLM Nutritionists are<a href="https://nutrition.ai/"> here</a> but are still limited by data inputs (they require food pics to be useful) so I’m not overly excited here because of the friction.</p><h3>3.1.6 Longevity-Specific Plays?</h3><h4>3.1.6.1 Care Team: Dietitians</h4><p>We worked with some AMAZING Dietitians at Curv Health — I learned so much from them about the impact a trained medical professional can have on a patient’s life</p><p>Because Dietitians are a registered, regulated health title in Canada — they ARE reimbursable under standard private health plans that include paramedical practitioner coverage. Because of these two points — I think any longevity focused play in Canada should include a Registered Dietitian</p><h4>3.1.6.2 Care Team: Nutritionists</h4><p>Nutritionists are not a registered title in Canada and therefore not reimbursable. This means you can use a single nutritionist across all 13 provinces and territories in Canada without worrying about the provincial restrictions. While they of <em>course</em> can be highly effective — one of the goals for a longevity play in Canada would be to maximize the number of services in the bundle that are reimbursable — so I would personally opt for Dietitians over Nutritionists if building here.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3f043004ea3e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Prescription Digital Therapeutics (PDTx): an Investor’s Guide]]></title>
            <link>https://medium.com/@markjgoad/prescription-digital-therapeutics-pdtx-an-investors-guide-c1de206d8fb8?source=rss-d9ca5d9d52a0------2</link>
            <guid isPermaLink="false">https://medium.com/p/c1de206d8fb8</guid>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[healthcare-technology]]></category>
            <category><![CDATA[digital-therapeutics]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[Mark Goad]]></dc:creator>
            <pubDate>Wed, 19 Feb 2020 13:15:48 GMT</pubDate>
            <atom:updated>2020-02-19T13:15:48.000Z</atom:updated>
            <content:encoded><![CDATA[<h3>Intro</h3><p>Technology<strong><em> </em></strong>has <em>long </em>been prescribed as a remedy for healthcare’s ailments.</p><p>Programmers in the 80s built expert systems (early AI) like the <a href="https://en.wikipedia.org/wiki/CADUCEUS_(expert_system)">CADUCEUS</a> to automate disease diagnosis.</p><p>IT providers in the 90s <a href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.19.6.57">proposed </a>networked health information systems that would increase consistency in care and generate robust data to better manage &amp; predict costs.</p><p>Startups in the early 2000s <a href="https://www.pewresearch.org/internet/2000/11/26/the-online-health-care-revolution/">claimed</a> the internet was a revolution for healthcare and was going to provide unlimited information, education, virtual interactions with your doc, and second opinions from experts around the world.</p><p>In the 2010s, the progress &amp; cost reduction of genome sequencing held promises of <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957753/">personalized medicine</a> that are still developing today.</p><p>It is the year <strong>2020 </strong>and most of our engagement with healthcare systems look similar to how they did 20 years ago. The cost of delivering healthcare (particularly in the US) has risen faster than inflation for decades but health outcomes for patients are mostly better.</p><p>Change in healthcare takes time. For every example of progress, we can point to over-hyped claims that failed to deliver. This assessment of ‘failure’ vs. ‘progress’ depends on the time horizon applied.</p><p>Today, we stand at the dawn of a new era of healthcare innovation. The smartphone — a device some of us (figuratively) cannot live without — as a new platform to deliver care. While assessing this new crop of innovative startups, it is important to balance historical adoption rates of technology with our enthusiasm for innovation.</p><h3><strong>You should read this article if you are interested in understanding:</strong></h3><ul><li>what Digital Therapeutics are &amp; the current state of the market;</li><li>a VC’s view of DTx risk &amp; upside;</li><li>DTx commercialization, stakeholders &amp; strategies;</li><li>what we think the DTx work will look like in 5 years.</li></ul><p>If you are building in this space — I’d love to <a href="/service/mailto:mgoad@omersventures.com">talk</a>.</p><h3>1. Overview of PDTx</h3><p>Prescription Digital Therapeutics (PDTx’s) are medical interventions which leverage software as the ‘main ingredient’ to prevent, manage or treat medical disorders or disease.</p><p>While there are many variants, this article will mainly discuss standalone PDTx apps – as opposed to apps built to support a connected health device (i.e. heart rate sensor, etc.) or associated pharmacological intervention (i.e. drug companion).</p><p><strong>PDTx’s are apps that treat diseases just as well as drugs.</strong></p><p>For us, PDTx’s are different from other ‘digital therapeutics’ or ‘disease management apps’ as PDTx’s are accredited by governing authorities to be distributed by primary care providers (i.e. approved by the FDA in the U.S. and prescribed by your doctor). Whereas digital therapeutics or disease management apps <em>may</em> have peer reviewed studies and be reimbursable by payers, but lack the clinical rigour imposed by regulatory scrutiny (more on this below).</p><p>Most PDTx’s focus on indications with a strong behavioural component — using the smartphone’s components that were originally designed for communication &amp; entertainment to capture, analyze, and transmit medical interventions.</p><p>Because the input vehicle is a smartphone, we can breakdown the common PDTx application components along the specifications of modern smartphones:</p><p><strong>Input Mechanisms (for collecting patient data)</strong></p><ul><li>Screen: often used to collect patient’s behavioural or cognitive status by administering tests/quizes (mood, cognition, memory, familial recognition, concentration);</li><li>Accelerometer: often used for measures of dexterity or steadiness (stretching, range of motion tests); and,</li><li>Microphone: often used for audio analysis (voice quality, shakiness)</li></ul><p><strong>Output Mechanisms (for delivering care)</strong></p><ul><li>Screen: for delivering content (blogs, tips, FAQs, videos);</li><li>Chat (Voice/Text/Video): for patient communications (professional coaching, peer-to-peer support); and,</li><li>Notifications: often used for adherence prompts (inactivity, sleep, diet).</li></ul><p>Using these input and output mechanisms, PDTx’s can be used to replace or augment existing treatments like counselling, devices, or drugs.</p><p>The industry is rushing to get their apps approved by the FDA (and similar regulatory bodies, globally) via the same rigorous clinical assessments that are required for Class II medical devices [more info below].</p><p>The most common indications treated by public FDA PDTx applicants are anxiety, depression, insomnia, pain management (typically via iCBT) and cardio metabolic conditions (typically via dieting/coaching) [see market map below].</p><h4>The Most Advanced PDTx Companies</h4><p>All public info from company websites; funding data from PitchBook:</p><p><a href="https://peartherapeutics.com/products/reset-reset-o/"><strong>Pear Therapeutics</strong></a>, developed the first FDA approved, software-only PDTx <em>reSET-O</em> (iCBT for opioid outpatients); and <em>reSET</em> for substance abuse disorder (FDA approval pending) with Sandoz, a division of the +$200Bn market-cap pharma giant Novartis. Sandoz and Pear recently cancelled their commercial agreement (more info below) [$139Mn funding].</p><p><a href="https://www.akiliinteractive.com/programs-products"><strong>Akili Interactive</strong></a>, which develops apps and games which treat ADHD (FDA approval pending), autism spectrum disorder, major depressive disorder, multiple sclerosis, and is currently developing products to treat traumatic brain injury, ICU delirium, and lupus. [$134Mn funding].</p><p><a href="https://gaia-group.com/en/"><strong>Gaia Therapeutics</strong></a>, develops PDTx’s for major depressive disorder (RCT study), borderline personality disorder, generalized anxiety disorder, panic disorder, social phobia, fatigue in multiple sclerosis, epilepsy and others. [Unknown — German company].</p><p><a href="https://www.clicktherapeutics.com/"><strong>Click Therapeutics</strong></a>, develops PDTx’s for major depressive disorder, insomnia, acute coronary syndrome, chronic pain, and migraines. [$17.5Mn funding — with $300Mn co-dev deal with Otsuka Pharmaceuticals in Japan].</p><p><a href="https://www.bettertherapeutics.io/"><strong>Better Therapeutics</strong></a>, develops PDTx’s for type two diabetes, hypertension, and hyperlipidemia. [$23.8Mn funding].</p><p><a href="https://www.naturalcycles.com/en"><strong>Natural Cycles</strong></a>, develops an FDA-approved contraception app and associated basal body temperature thermometer to assess risk of pregnancy. [$38Mn funding].</p><h3><strong>2. Why is PDTx Venture-backable?</strong></h3><p>Four big reasons why we (a software-focused venture fund) like the idea of PDTx:</p><h4>a) Software can influence behavior.</h4><p>We know that software influences behavior (shout-out Zuck) and most diseases have a meaningful behavioral component.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/644/1*_-71-ZFnkz3WFYzDDUkGpQ.png" /></figure><h4><strong>b) Bits over atoms.</strong></h4><p>We are familiar with the <strong>near-zero-marginal-cost-of-reproduction economics </strong>of software businesses and have seen how scalable these businesses are relative to non-software competitors (in this case — pharmaceuticals). We are also comfortable with the archetypal software startup journey with associated fundraising milestones, metrics, and operating strategies.</p><p>Further, as your app’s ML and DL algorithms are deployed to more devices and patients, we have seen accumulating accuracy that these models produce over time, meaning your solution could get better over time — something drugs cannot possibly claim (more on the FDA’s treatment of unauditable<strong> </strong>algorithms below).</p><h4>c) “Healthcare is a big business”</h4><p>VC platitudes be damned, Americans spend a lot of money on prescription drugs on an absolute and per capita basis, making it a great target for disruption via software.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/826/0*ViAAu6PbsxdUq9ax.jpg" /></figure><p>According to the Centers for Medicare and Medicaid Services, the U.S. spent $360.3 billion on prescription drugs in 2019. If a fraction of that spend can be diverted to high-margin software applications that actually work — there will be strong investor interest.</p><h4>d) Alternatives to PDTx (i.e. drugs) are expensive</h4><p>Finally, the cost of drug development has climbed substantially as the ‘low-hanging-fruit’ of pharma has been captured over the last few decades and R&amp;D and regulatory costs continue to rise.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/300/0*IMhcQZZUMsClJWu9.jpg" /><figcaption>CSDD Research</figcaption></figure><p>According to a study by Tufts Center for the Study of Drug Development (CSDD) published in the Journal of Health Economics, the average cost of developing a drug that gains marketing approval by the FDA reached $2.6 billion, up from $802 million in 2003 (CAGR of 9.5% over 13 years).</p><h3>3. A framework for measuring PDTx progress</h3><p>After talking to +50 teams building in the space, we have traced the evolution PDTx startups follow, with associated funding milestones. Note: there are certainly companies that buck the outline below – I am stating the general trends we see – not the mandatory or required progression.</p><h3>Level 1: Validation</h3><p><em>Financing Stage: Seed</em></p><p>The first wrung on the journey of a PDTx startup is building an MVP of your app and testing it with a small group of users to prove it has an impact on a specific indication. Most startups we engage with have a product and have run studies with small (10–50) groups of users with positive results.</p><p>These teams are usually out actively fundraising for a sizable ($10-$25Mn) Series A with this evidence to convince investors to fund the <a href="https://www.fda.gov/media/87363/download">FDA clinical trial process</a>.</p><p><strong><em>The needle to thread</em></strong><em>: </em>teams have limited money to run massive, complex studies — but investors need solid clinical results to be enticed to take on FDA/regulatory risk to fund the business at this stage.</p><p>Essentially, you are asking investors to extrapolate the results of exploratory trials to the FDA’s rigorous design &amp; control thresholds.</p><p>The best teams we see at this stage have designed their early studies with robust controls that are at least analogous to the studies used by more mature FDA applicants.</p><p>Plenty of academic literature exists to help us classify and rank studies based on size, design, quality of evidence, and risk of bias.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/850/0*rzaFCir2cNiBCbRp.png" /><figcaption>The Hierarchy of Evidence Pyramid, ResearchGate</figcaption></figure><p>We have seen a few teams get a massive head-start here by leveraging relationships with existing healthcare providers to grow their validation patient population at a significantly reduced cost. One team was working to develop a PDTx for depression and was already engaged with a group of psychotherapy clinics via a chat and patient management application to get detailed data on patients and outcomes to optimize their solution. This is an incredibly attractive way for teams to de-risk this stage of product development and is an early signal you are able to navigate the complex ecosystem of healthcare stakeholders.</p><p>Assuming studies are designed with sufficient quality of evidence and controls for bias, investors are next looking to the delta in cost &amp; performance relative to the existing standard of care for that particular indication. Whether or not you believe the alternative needs to be <a href="https://www.amazon.ca/Zero-One-Notes-Startups-Future/dp/0804139296/ref=sr_1_1?gclid=CjwKCAjwusrtBRBmEiwAGBPgEyGinElM3TSpb8mM7kACFKPrnp-z93ZiR5jgvf8383dkoLG7GP0KoBoCP9wQAvD_BwE&amp;hvadid=325039529512&amp;hvdev=c&amp;hvlocphy=9061009&amp;hvnetw=g&amp;hvpos=1t1&amp;hvqmt=e&amp;hvrand=17356652139781893540&amp;hvtargid=aud-749198100220%3Akwd-317621378788&amp;hydadcr=16963_10238181&amp;keywords=%27zero+to+one%27+by+peter+thiel&amp;qid=1572009121&amp;sr=8-1">10x better</a>, relative performance will matter to patients when they are presented with more established alternatives. Establishing clear performance improvements relative to existing standards of care is not an easy task – but the best teams we see have very clear data that shows the efficacy of their solution.</p><h3>Level 2: Efficacy</h3><p><em>Financing Stage: Series A</em></p><p>Typically after the Series A is raised, these startups apply for either a De Novo or 510(k) approval from the FDA.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*WLah9f7lphYuPnORUgxnyQ.png" /></figure><h4>FDA</h4><p>The De Novo program is for new devices (apps) that have no substantially equivalent predecessor (as determined by this <a href="https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k#se">test</a>) while 510(k) clearance is for apps that have sufficient similarity to existing solutions.</p><p>Typically, we see PDTx startups first apply for the more rigorous De Novo program for their first solution/indication and leverage their technology platform to build subsequent solutions in adjacent indications which they can route via the less strenuous 510(k) path.</p><h4>Microservices</h4><p><a href="https://www.clicktherapeutics.com/">Click Therapeutics</a>, one of the leading PDTx startups, detailed their microservices architecture (from their public website) which categorizes services into behavioral and medical to show how they can build multiple apps for multiple indications by routing new content onto existing, modular service components.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*WZteQB7I63DSwlaj6nnleA.png" /><figcaption>modified from Click’s website, June 2019.</figcaption></figure><h4>Machine Learning &amp; Deep Learning</h4><p>A theme dominating discussions with PDTx’s is the FDA’s view on unauditable ML/DL algorithms.</p><p>Important concepts include (1) <a href="https://www.kdnuggets.com/2018/12/machine-learning-explainability-interpretability-ai.html">interpretability</a>: being able to discern what the algorithm is doing, without necessarily knowing why, and (2) explainability, which is being able to literally explain what is happening and why an algorithm is making a specific recommendation.</p><p>This matters to the FDA, because depending on the type of ML/DL algorithm deployed, developers may not be able to fully explain why their app is making a specific recommendation.</p><p>Traditional programming involves the application of rules to data to provide an answer. For PDTx, that would looks like this:</p><ul><li>Patient provides data (i.e. I’m feeling depressed today, subsequent details of severity, duration of symptoms, etc.)</li><li>Application applies rules (i.e. based on measures of severity &amp; duration — either take deep breaths, go for a walk, meditate, or if more concerning, seek medical help).</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/850/0*tksN4U-Fzwn6NUx_.png" /><figcaption>Hubert Wang, Introduction to TensorFlow for AI, ML, and DL</figcaption></figure><p>In ML/DL, specific outcomes and the preceding subject data are supplied and the algorithm builds the rules (whether or not fully-explainable) that connect the answers to the underlying data. Using a simple regression or random-forest analysis — it is simple to attribute the relationships between the data and explain the app’s recommendation. However, as researchers continue to deploy more complex, multi-level neural networks — these connections become increasingly obfuscated.</p><p>The FDA has generally communicated (via PDTx conferences and in conversations with startups) that it will govern ML/DL algorithms using the existing principals of efficacy and immaterial changes. Essentially, if the models produce effective recommendations at scale in well-controlled studies, they will continue to be approved. Regarding the re-enforced, self-learning (i.e. changing nature) of ML/DL algorithms, regulators have communicated as long as the changes are gradual and within reasonable windows of efficacy that the solution was initially approved, they will remain supportive.</p><h4>Aglie Development as a Precursor</h4><p>The concept of software updates and patches are not new to the FDA, which in 2013 <a href="https://www.linkedin.com/pulse/fda-perspective-agile-methodology-healthcare-neetu-yadav/">worked with software engineering teams</a> during the industry’s macro shift from waterfall to agile development methodologies, allowing teams to use short-term development sprints that add incremental functionality and performance improvements to their FDA regulated software without requiring review every time new code was pushed to production and patients.</p><p>We believe the FDA will continue to manage ML/DL based applications under these guiding principals.</p><h3>Level 3: Integration</h3><p><em>Financing Stage: Series B</em></p><p>The next milestone we see are startups who have completed, or are nearly finished, their FDA pre-market approvals and are beginning to test go-to-market strategies in preparation for launch. These teams are usually raising their Series B financing, in the range of $20–$50Mn.</p><p><strong><em>The needle to thread</em></strong>: convincing payers this PDTx is worthy, convincing providers it is effective, convincing patients it will work for them.</p><p>Go-to-market strategies for PDTx vary widely, with different strategies for different disease indications and provider/payer/patient paradigms.</p><h4>Integration with Providers</h4><p>Providers include anyone who provides care: doctor, chiropractor, clinical psychologist, optometrist, nurse practitioner, dentist, clinical social worker, etc.</p><p>We have talked to a lot of providers about PDTx — from primary care physicians, psychologists, and dentists. Their concerns are persistent across focus areas and can be bucketed by constraints on time &amp; concerns over efficacy:</p><p><strong><em>Time</em></strong></p><ul><li>I have a lot to do (their schedules are insane) and I didn’t ask to read your BDR’s crappy outreach email.</li><li>I don’t have time to learn about new apps.</li><li>Even though it’s enabled by your app, how am I supposed to check-in with my patients when they’re not in an appointment? What is a reasonable cadence? What reminders will you provide?</li><li>No EMR? No go. Some physicians draw the line if they have to log in to a separate web-app to monitor or report on performance.</li></ul><p><strong><em>Efficacy</em></strong></p><ul><li>I don’t trust your 10-person, VC-funded clinical trial — show me something more robust.</li><li>You told me EMR’s (aka technology) were going to change the way I treated patients, they haven’t delivered on any of that value I was promised — why should I trust you now.</li><li>I don’t trust unauditable deep learning algorithms.</li></ul><p>For us, integrating with providers represent an important hurdle for any PDTx startup. Leading companies at this stage have practicing representatives from their domain advising on this engagement strategy. Repeatedly in these conversations, and similar to other industries, the importance of winning over key opinion leaders in specific domains is paramount so they can validate the solution for other providers.</p><h4>Integration with Payers</h4><p>Payers pay for healthcare. In the U.S., most Americans have insurance (91%) and are covered by their employers (67%).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*anFw-f2nvVrhzrF6RlWwvg.png" /></figure><p>Payers are employing ‘measured optimism’ regarding PDTx. They see the cost of delivering healthcare first-hand that is forcing them to charge more while delivering the same or less value. PDTx looks like an amazing way to meet their members where they already spend time (on their phones) and deliver meaningful no-drug interventions.</p><p>However, most PDTx preventative solutions are just too nascent to truly <em>prove </em>they will deflect or reduce future health care spending (i.e. panic attacks leading to emergency room visits) and most treatment solutions suffer from the same lack of clinical data to establish they can manage harmful diseases, especially in complex co-morbidity scenarios which drive the majority of costs for payers.</p><h3>Efficacy vs. Effectiveness</h3><p>Payers play the important role of selecting which PDTx’s they will reimburse for their members. From payers, we hear the selection criteria will involve the important distinction between efficacy and effectiveness. Efficacy refers to the performance of an intervention under ideal conditions (i.e. in a controlled trial environment) while effectiveness describes performance under normal circumstances of use (i.e. real life). Many payers we spoke with expressed skepticism of claims being made by PDTx’s from their initial studies and talked about how they may require additional clinical trials to address their concerns before supporting a PDTx.</p><h3>Adherence (=? Retention)</h3><p>The biggest gap between efficacy and effectiveness we see in PDTx’s today is that retention mirrors what we see in some consumer applications: a massive cliff between signup and week 1 and a steady, unrelenting decline from there. More often we see teams try to hide poor engagement data when we would rather see it benchmarked to the existing standard of care. Here’s why: drug adherence is empirically awful. From the CDC:</p><blockquote>In the United States, 3.8 billion prescriptions are written annually. Approximately one in five new prescriptions are never filled, and among those filled, approximately 50% are taken incorrectly, particularly with regard to timing, dosage, frequency, and duration. Whereas rates of nonadherence across the United States have remained relatively stable, direct health care costs associated with nonadherence have grown to approximately $100 – $300 billion of U.S. health care dollars spent annually. From: Improving Medication Adherence for Chronic Disease Management – Innovations and Opportunities (2017).</blockquote><p>A 20% drop from signup to week 1!! 50% adherence thereafter! The reasons for nonadherence are critical in this evaluation:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/898/0*n6Hp-nE8Yi9boQ7o.gif" /><figcaption>CDC: Improving Medication Adherence for Chronic Disease Management</figcaption></figure><p>The top three reasons SHOULD be addressable given the inherent properties of PDTx: forgot, ran out, left at home (a big reason why we think Providers/Payers are excited – but haven’t seen enough data to support this). Even when we see strong adherence, we often have this lingering unease as to whether the Hawthorne effect (where people behave differently when they know they are being watched) is present in small scale trials with people more regularly touching base with clinicians thereby resulting in artificially high engagement. Addressing these concerns head on with study design constrains can help assuage these investor concerns.</p><p>A corroborating datapoint for benchmarking adherence is digital health company Livongo, which <a href="https://www.sec.gov/Archives/edgar/data/1639225/000119312519185159/d731249ds1.htm">IPO’d</a> in July, and publishes enrollment data for its corporate and health system customers. Livongo is best known for its diabetes management application which helps patients manage their blood sugar levels with a bluetooth-enabled blood glucose meter and associated app that provides personalized recommendations (I refuse to say ‘health-nudges’) for diet, exercise, and related behavioural changes. In its S1, Livongo marked its 12-month enrollment for new customers at 34% of total recruitable patients. Most PDTx startups we speak to speculate that this rate is relatively low because Livongo primarily acquired its 148,000 members through their employers — who have a weaker relationship when it comes to healthcare than a primary care physician who would prescribe a PDTx. In most cases, it is too early to establish what a ‘good’ enrollment and adherence rate is between PDTx’s and we prefer to use existing drug adherence as the baseline.</p><p>Adherence is a key value proposition for DTx and PDTx startups. Providers, patients, and investors are excited about the smartphone as a delivery vehicle for healthcare given we can’t seem to live without our devices. However, early data from the industry suggests that this does not necessarily translate into continued usage and adherence — making this point a key aspect of our early diligence efforts.</p><h3>Marketplace Approach with many PDTx’s</h3><p>However, once a PDTx solution can pass this effectiveness bar (which varies by payer and indication), payers have publicly stated that their intention is to have many solutions for each indication. Most payers have created or are in the process of building directories of approved applications that will allow members to self-select their desired intervention, as advised by their provider.</p><p>The most advanced public offering is <a href="https://www.prnewswire.com/news-releases/blue-shield-of-california-launches-new-digital-therapeutics-platform-to-help-members-prevent-treat-and-potentially-reverse-diseases-300875475.html">Blue Shield of California’s Wellvolution platform</a>. We expect most payers to employ a similar ‘centralized’ distribution strategy because if the app is accessed via their platform, it makes tracking engagement, usage, and subsequent billing more streamlined for the payer but puts the burden of integration on the PDTx.</p><p>We also have seen pharmacy benefits managers begin to curate formularies (lists of medicine) for digital products that payers can select for their members. Both CVS <a href="https://medcitynews.com/2019/06/cvs-caremark-launches-new-platform-to-better-integrate-innovative-wellness-solutions/">Caremark </a>and <a href="https://medcitynews.com/2019/05/express-script-prepares-to-launch-stand-alone-digital-health-formulary-in-2020/?rf=1">Express Scripts</a> have announced they will offer lists of pre-vetted solutions that have been screened for “safety, effectiveness and usability”.</p><h3>Level 4: Efficiency</h3><p><em>Financing Stage: Series C</em></p><p>Now that a PDTx has been approved by the FDA, integrated with providers &amp; payers — the go-to-market race begins. We remain concerned that some teams forecast this to be an ‘easy’ step and envision monopolistic markets in which they are the only PDTx for their indication – with the specific rationale that the FDA approval process is a definitive and enduring moat… but is FDA approval a competitive moat?</p><h4>The FDA and Drug Patents</h4><p>Hear me out. If we believe that software can influence behaviour and most diseases have a key behavioural element, we should expect to see a significant increase in the number of PDTx startups over the next few years. Further, recession predictions aside, in a world awash in (venture) capital, there should be sufficient funding for most PDTx teams to pursue FDA approval. The FDA and payers have both indicated their desire to have multiple solutions for each indication — allowing the consumer to select the intervention that best suits their unique needs. While we expect the first apps through the gate will have a relative advantage compared to the <a href="https://venturebeat.com/2019/05/26/digital-therapeutics-look-ready-to-bloom-with-help-from-pharma-companies/">350,0000 non-FDA-approved, health &amp; fitness apps</a>, we expect most widespread, behaviour-based indications to have multiple PDTx and disease management alternatives — and we are already seeing this with multiple competitors in behavioural health, diabetes, and hypertension.</p><p>In pharmaceuticals, economic moats are built by patents to guard market access before generic versions of the drug are sold at a far lower cost because competing pharmaceutical companies did not bear the cost of discovery. While the true length (and value) of drug patents depends on who you ask (industry watchdogs say too long; pharmaceutical companies say too short) a similar regime does not appear to exist for software businesses.</p><p>We generally do not get excited by software patents as moats because we often see multiple approaches that solve the same issue at the application layer (very different for infrastructure and middleware) — and filing a software patent complaint is <em>usually</em> a long and expensive process with uncertain outcomes. Applying this lens to PDTx, we see multiple apps treating the same indication which would not necessarily infringe on each other’s patent protections as there are many ways to influence an individual’s behaviour and treat a disease.</p><p><strong>Fundamentally, we see patenting PDTx software as a much weaker economic moat than patenting molecular composition.</strong></p><p>We predict that success for a PDTx startup will at first be correlated to the substantive, proven efficiency of the intervention, such that it is driven by payer and provider buy-in and pushed down to consumers (patients). We expect long-term market success to be more pull-through, relying on a combination of distribution, positioning, and product efficacy — more similar to the success formula for consumer apps than pharmaceuticals (see section #5 below).</p><h4>Partnerships with Pharma</h4><p>Three of the leading PDTx’s have announced partnerships with pharmaceutical companies in an apparent exchange of digital-learning for commercialization expertise.</p><p><a href="https://peartherapeutics.com/">Pear Therapeutics</a>, the developer of the first-ever software-only <a href="https://www.fda.gov/news-events/press-announcements/fda-clears-mobile-medical-app-help-those-opioid-use-disorder-stay-recovery-programs">FDA approved</a> PDTx (December 2018) reSET-O, a prescription iCBT app for opioid drug addiction, <a href="https://www.sandoz.com/news/media-releases/sandoz-signs-agreement-pear-therapeutics-develop-and-commercialize-prescription">partnered </a>with — and subsequently <a href="https://www.mobihealthnews.com/news/north-america/novartis-cutting-its-digital-therapeutics-commercialization-partnership-pear">cancelled </a>— their go-to-market partnership with Sandoz, a division of Swiss pharma giant Novartis.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Hbjp718koXgWtaUkSko04A.png" /></figure><p><a href="https://www.clicktherapeutics.com/">Click Therapeutics</a>, the developer of the behavioural &amp; medical microservices platform for PDTx’s outlined above, partnered with Japan’s <a href="https://en.wikipedia.org/wiki/Otsuka_Pharmaceutical">Otsuka Pharmaceutical</a> to co-develop a new PDTx to treat depression with up to $300Mn in payments available if commercial (GTM) milestones are achieved.</p><p><a href="https://www.akiliinteractive.com/">Akili Interactive</a>, the developer of digital medicines (some are video games) for cognitive diseases has partnered with Japan’s Shionogi pharmaceutical (best known for developing Crestor), who has purchased the exclusive rights to the clinical development, sales and marketing of Akili’s ADHD and autism treatment apps in Japan and Taiwan.</p><p>We generally see pharmaceutical companies engage reticently with PDTx startups. On one hand — the transition of value from <em>atoms to bits</em> has decimated many other industries and most big pharmaceutical companies have venture arms and corporate development groups to flag incoming disruption to their drug portfolios. Most of these groups are taking a balanced approach to build vs. partner vs. buy — building what is closest to their core, or has the best chance of extending their marquee patents which generate a disproportionate share of their revenue and earnings. When speaking to one pharma executive — I posited that pharma hiring software engineers is similar to the automotive industry hiring for these roles: “not the engineer they usually go for”. There is sufficient operating budget to build these teams — but definitely a deficit in organizational design and incentives that will levy a ‘strategy tax’ on these efforts. Most pharmas appear to be happy to monitor competing PDTx solutions while only the three above have jumped in to the market with partnerships. Of note, we have not seen any big acquisitions/investments (like VW Group’s <a href="https://techcrunch.com/2019/07/12/vw-invests-2-6-billion-in-self-driving-startup-argo-ai-as-part-of-ford-alliance/">$2.6Bn investment</a> into Argo) … yet.</p><h3>Level 5: Engagement</h3><p>Financing Stage: Series D+</p><p>The final level of PDTx startup we foresee, but have not seen in the market today, is one that goes beyond transactional GTM partnerships with existing pharmaceutical companies and engages patients with product, acquisition, and retention techniques we see in leading consumer, social and gaming applications. I generally detest the word ‘gamification’ — in my view it has been co-opted by tired enterprise PMs seeking better engagement by draping game mechanics over existing, crappy applications.</p><p>However, game mechanics, social mechanics, viral loops, and feedback cycles are not optimizations done after the fact, but built into the heart of the product experience from day 1. While some VR-focused PDTx’s have hired some game designers (typically building virtual worlds on engines like Unity) we see far fewer companies incorporating modern product management principals into their applications.</p><p>From one side — it makes sense. Delightful product experiences will not appease the FDA.</p><p>But if you agree with our thesis that multiple PDTx’s will serve the same indication, available from the same providers, payers, and regulators — then you should be similarly concerned that the industry is deferring investment (or at least mindshare) on what we view as an essential element of PDTx long-term differentiation. As we have seen from the legacy enterprise software providers — it is incredibly hard to add these product elements after the fact.</p><h3>Want to chat?</h3><p>PDTx’s represent a tremendous opportunity to deliver medical interventions at a global scale with nominal margin cost. The VC-backed startups building in the space employ a wide range of regulatory, product development, and go-to-market strategies — and the playbook looks quite different from a traditional enterprise SaaS company.</p><p><a href="https://www.omersventures.com/">OMERS Ventures</a> leads Series A-C investments, usually with a USD$10-$30Mn check from our Toronto, London, &amp; Bay Area offices. Existing investments in the future of health include musculoskeletal (MSK) health pre-hab and rehab solution <a href="https://www.peerwell.co/">PeerWell </a>and <a href="https://league.com/ca/">League</a>, which is building a new OS for employee health benefits with major employers across North America.</p><p>We’re looking for teams that can outperform the general path I’ve outlined above and are typically on stage #3(clearing regulatory risk), have some early data of their GTM integration with payers and providers, and share our thesis of a multi-competitor world so are building incredibly engaging PDTx apps.</p><p>If you are intrigued/enraged by this article — my email is mgoad@omersventures.com</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c1de206d8fb8" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Current State of Depression]]></title>
            <link>https://medium.com/@markjgoad/the-current-state-of-depression-2e03ca752b8d?source=rss-d9ca5d9d52a0------2</link>
            <guid isPermaLink="false">https://medium.com/p/2e03ca752b8d</guid>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[depression]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[Mark Goad]]></dc:creator>
            <pubDate>Fri, 01 Feb 2019 15:52:58 GMT</pubDate>
            <atom:updated>2019-02-01T16:44:26.881Z</atom:updated>
            <content:encoded><![CDATA[<h3>Part 2 of 2</h3><p><em>A two-part report on the global depressed population; the role of technology in causing depression; and a VC’s investment framework for solutions.</em></p><p><a href="https://medium.com/@goader92/the-current-state-of-depression-f0604393c78e"><strong>Part 1</strong></a> looks past the current hype (read: media coverage) around depression to primary census data to understand if there are structural changes in the global depressed population over the last 20–60 years (country/data dependent).</p><p><strong>Part 2 </strong>proposes OMERS Ventures’ investment framework and looks at interesting startups across the life-cycle of care for depressed patients.</p><p>Special thanks to the leadership team at <a href="https://medium.com/u/1b8d4a5567c9">OMERS Ventures</a> who supported me with time, intros, and resources to pull together this research over the past few months.</p><h3>3.0 Mental Health Technology Funding Ecosystem</h3><p>Venture capital funding of mental health, mindfulness, and therapy startups has exploded over the past decade, increasing by 8.3x since 2013. Since 2015, mental health technology startups have raised USD $1.5 billion in venture capital funding. <a href="#_ftn1">[1]</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/618/1*Flry5af9Al8fr0vQLBfWkw.png" /></figure><p>Funding has historically been directed to US companies but we are seeing an increasing flow of capital towards Asian startups focusing on mental health.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/630/1*G5zxbNd3IbaMKL9BxRf0rw.png" /></figure><p>Mental health is a global affliction that we believe is highly localized by region-based cultural norms and public health policies. We expect to see localized solutions, treatments, and investment opportunities that reflect the nuances of regional markets.</p><h3>4.0 OMERS Ventures’ Patient Journey Investment Framework</h3><p>We propose a value-based framework to align potential technology-enabled solutions to the lifecycle of patient care: subclinical (does not meet the clinical threshold for depression), diagnosis, treatment, and post-treatment. Using this methodology, we can segment investment opportunities by their place in the lifecycle of care for a depressed patient.</p><h3><strong><em>Figure 12.0 OV’s Patient Journey Investment Framework</em></strong></h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*yc8nLJW6h90HHuyQ3Zn5Vg.png" /></figure><p>Subclinical and Post-Treatment are denoted as distinct phases with the key difference being that a patient in post-treatment lives with the diagnosis of depression despite having completed treatment. This is in contrast to an individual in the Subclinical zone who may be dealing with some or all of the symptoms of depression but has not been diagnosed and therefore has different treatment needs and expectations for technology solutions.</p><h3>4.1 Pre- Diagnosis or Subclinical Depression</h3><p>Before a clinical diagnosis of depression, technology can support those living with psychological stress and even mild to moderate symptoms of depression.</p><h4>4.1.1 Meditation — Mobile Applications</h4><p>Mobile meditation and mindfulness apps like <a href="https://www.calm.com/">Calm</a>, <a href="https://www.headspace.com/">Headspace</a>, <a href="https://buddhify.com/">Buddhify</a>, <a href="https://insighttimer.com/">Insight Timer</a>, <a href="https://awaremeditationapp.com/">Aware</a>, and others have been shown to reduce psychological stress and can be as effective as pharmacological solutions for patients with mild mental ailments, including depression.<a href="#_ftn2">[2]</a> Calm and Headspace are the leading mediation applications, having raised USD $28.3 million and USD $74.3 in venture financing respectively. Calm most recently reached a post-money valuation of $277 million led by Insight Venture Partners with participation from Ashton Kutcher’s Sound Ventures.</p><p><em>Company Spotlight</em></p><p><a href="https://www.10percenthappier.com/">10% Happier</a> has built a meditation app for skeptics of meditation. The app is based on Dan Harris’ bestselling novel of the same name and offers expert advice via text and video content from scientists, psychologists, meditation teachers, and athletic psychologists who have worked with the Chicago Bulls, LA Lakers, and NY Knicks. The company has raised USD $5.6 million from Trinity Ventures, Coastal Ventures, Khosla Ventures, and others. I personally loved Dan’s story of how we went from skeptic to believer, with biographical vignettes that complete the narrative.</p><p><a href="https://www.simplehabit.com/">Simple Habits</a> helps busy professionals squeeze mindfulness into their day in 5-minute increments. The idea came to Yunha Kim, a tech founder who sold her last app to Wish in 2015 and wanted a better way to find peace in her hectic days. Simple Habit has raised USD $2.5 million from Foundation Capital, FJ Labs, Y Combinator, and Drew Houston of Dropbox.</p><p><strong><em>Investor Takeaway: We believe mediation applications will continue to play an important role in alleviating mild psychological distress but will be unable to replace psychological and pharmacological treatments for patients suffering from moderate to severe depression.</em></strong></p><h4>4.1.2 Meditation — Physical Accessories</h4><p>Headbands that monitor brainwaves can augment the meditation experience by guiding patients through the process. The <a href="http://www.choosemuse.com/">Muse</a> headband by InteraXon (an OMERS Ventures portfolio company) is a leading product in this category and is recommended by mental health professionals to help patients suffering from mild to moderate depression and anxiety. InteraXon has raised USD $29.8 million in venture financing from OMERS Ventures, Horizon Ventures, and others.</p><h4>4.1.3 Meditation — Technology-Enabled Meditation Clinics</h4><p>Ultra-premium meditation clinics have emerged that leverage technology to enhance the quality of meditation across a spectrum of mindfulness experiences. <a href="https://www.inscape.life/">Inscape</a> is an example of a vertically integrated studio with a physical location in Manhattan and a corresponding iPhone application that guides users through meditation experiences in the studio and outside to provide a comprehensive wellness solution. <a href="https://www.mindsetbraingym.com/">Mindset Brain Gym</a> in Toronto features a lounge with <a href="https://nanoleaf.me/en-ca/">Nanoleaf LEDs</a> that alter the ambiance of the room by adjusting to the tone and pace of the music, Muse headsets to track brain activity and stillness pods with six prerecorded guided meditation lessons projected from 3D-audio immersive speakers.</p><h4>4.1.4 Employer Solutions — Wellbeing Assessments</h4><p>Wellbeing assessment solutions are a category of enterprise applications that extend traditional Human Resource Information Systems (HRIS) with modern survey tools to get a snapshot of the organizational health and capture data specifically regarding mental health.</p><p><em>Company Spotlight</em></p><p><a href="https://league.com/ca/home/">League</a> (an OMERS Ventures portfolio company) is a modern employee benefits platform that enables employees to actually use their benefits (i.e. health, dental, insurance, professional development, etc.), earn points for completing fitness challenges, and spend their balances on exclusive offers in the application’s marketplace from leading health and fitness brands, all via a consumer-grade mobile experience. The company has raised USD $76.2 million from OMERS Ventures, TELUS Ventures, the Royal Bank of Canada, BDC Capital IT Fund, and others.</p><p><a href="http://www.psyt.co.uk/">me@mybest</a> by PSYT Psychological Technologies is a people analytics platform that surveys employees’ holistic wellbeing and provides anonymized insights back to managers to guide their people and talent strategies. Along this vein of solutions, LinkedIn recently paid a <a href="https://techcrunch.com/2018/10/08/linkedin-acquires-employee-engagement-and-retention-platform-glint/">rumored USD$400 million</a> to acquire employee survey application Glint which does not specifically focus on mental health — but we expect this to be on their survey roadmap.</p><p><a href="https://www.unmind.com/">Unmind</a> is a workplace mental health platform that provides scientifically-backed HR, coordination, and mindfulness applications with enterprise grade analytics, insights, and support features. The company was founded in 2016 and is based in the UK with no funding data available on PitchBook.</p><p><a href="https://www.lifeworks.com/us/">LifeWorks</a> (acquired in July 2018 by <a href="https://www.morneaushepell.com/ca-en">Morneau Shepell</a> for <a href="https://www.newswire.ca/news-releases/morneau-shepell-completes-acquisition-of-lifeworks-corporation-ltd-and-231-million-equity-offering-689331581.html">CAD$426 million</a>) takes a holistic approach to mental, financial, psychical, and emotional wellbeing in a single, mobile-first platform with access to 24/7 counselling, expert mental health content, fitness challenges, and doctor-supervised assessments.</p><h3>4.2 Diagnosis</h3><p>Technology can play a leading role in diagnosing depression. Considering that most experts agree depression is underreported or undiagnosed due to cultural stigma and lack of access to mental health care services (see Part 1), using technology to help flag or diagnose depression presents a meaningful way to impact patients’ lives.</p><h4>4.2.1 Depression Screening Tools</h4><p>Developers have encoded standardized medical screening tests for depression, like the Patient Health Questionnaire-9 (PHQ-9), the Center for Epidemiological Studies-Depression Scale, or the Hamilton Rating Scale for Depression (HRSD) onto smartphone apps.</p><p><em>Company Spotlight</em></p><p><a href="https://www.moodpath.de/en/">Moodpath</a> asks daily questions to screen for symptoms of depression. By using the questions to measure users’ well-being and screen for symptoms of clinical depression, the app seeks to increase users’ awareness and understanding of their thoughts and feelings.</p><h4>4.2.2 Voice-based Diagnosis</h4><p>Voice-as-the-interface exploded in 2017 and 55% of all households in the US will have a voice enabled device, like an Amazon Echo, Google Home, or Sonos One, by 2022.<a href="#_ftn3">[3]</a> Seeing the opportunity to collect and analyze rich voice data, researchers at MIT used neural network models to learn patient speech patterns and predict depression in clinical interviews.<a href="#_ftn4">[4]</a></p><p><strong><em>Investor Takeaway: w</em>hile still early into the research, we expect to see increasing investment into voice and video diagnostic systems for mental health.</strong></p><h4>4.2.3 Text-based Diagnosis</h4><p>Researchers have been using natural language processing (NLP) models to detect depression-related cues from language for over three decades. Recently, researchers at Indiana University applied NLP models to 12,106 Reddit users’ posts and could diagnose depression markers with reasonable accuracy for use in large-scale community monitoring.<a href="#_ftn5">[5]</a></p><p><em>Company Spotlight</em></p><p><a href="https://www.koko.ai/">Koko.ai</a> is a company that pivoted from voice-based depression monitoring to text-based community health monitoring. The team is out of MIT and has raised USD $2.6 million from Union Square Ventures and Omidyar Network.</p><p><strong><em>Investor Takeaway: </em>we expect to see an increased investment in teams building that can accurately monitor massive amounts of user generated content, with text likely being a secondary focus to both voice and video.</strong></p><h4>4.2.4 Behavior-based Diagnosis</h4><p>A less invasive approach to diagnosis is passively collecting data and metadata from a user’s digital exhaust to establish a virtual profile of their behavior and periodically compare this profile to either the user’s past actions or an aggregate benchmark from other users. This approach is enabled by our passive creation of location, call, SMS, and app usage data from our smartphones.</p><p><em>Company Spotlight</em></p><p><a href="https://mindstronghealth.com/">Mindstrong Health</a> is a monitoring app that takes cues from the way a user types, taps and scrolls while using their phone to determine a user’s baseline mental cognition from the number of errors they make while typing or how quickly they scroll a list of contacts. Using machine learning, the app can notify both the user and their health care professional when usage deviates and there is evidence of mental health risk.</p><h3>4.3 Treatment</h3><p>Once diagnosed with depression, technology can be incorporated to a comprehensive treatment plan to extend and amplify traditional pharmacological and psychological treatment regimens.</p><h4>4.3.1 Psychological Treatment Apps: Cognitive Behavioral Therapy</h4><p>There is a group of apps including <a href="https://golantern.com/">Lantern</a>, <a href="https://play.google.com/store/apps/details?id=com.excelatlife.depression&amp;hl=en_CA">Depression CBT Self-Help Guide</a>, <a href="https://itunes.apple.com/ca/app/whats-up-a-mental-health-app/id968251160?mt=8">What’s Up</a>, and <a href="http://www.bonfireda.com/iCBT.html">iCBT</a> that have codified the popular treatment regimen Cognitive Behavioral Therapy (CBT) into a mobile experience for patients. CBT is a leading psychotherapy modality that has users question their base assumptions about their current and future experiences which creates negative or unwanted emotions. Interviews with psychotherapists suggests that while an app will be less responsive than a medical professional who also has the benefit of collecting information about the patient’s tone and speed of voice, body language, and other non-verbal cues, a patient who is previously trained in CBT may get significant value from a guided self-reflection.</p><h4>4.3.2 Mood Tracking Apps</h4><p>Mood tracking apps like <a href="https://itunes.apple.com/us/app/daylio-journal-diary-moods/id1194023242?mt=8">Daylio</a>, <a href="https://itunes.apple.com/us/app/moodhacker/id842771416?mt=8">MoodHacker</a>, <a href="http://www.thriveport.com/products/moodkit/">Moodkit</a>, and <a href="https://2appstudio.com/moodcast/">Moodcast</a> allow users with depression to record their general mood and activities and provide patients them with a sense of progress and temporality.</p><p><em>Company Spotlight</em></p><p><a href="https://www.thinkpacifica.com/">Pacifica</a> does mood tracking, meditation guides, goal setting, thought critiquing, as well as peer support via shared stores and advice from other patients. The company raised a USD $1.4 million seed from LEO Innovation Lab, HealthX Ventures, and PHS Capital.</p><p><strong><em>Investor Takeaway: given the relatively simple nature of these applications, which largely differentiate based on brand/interface, we do not expect to see a significant amount of venture investment into this specific category.</em></strong></p><h4>4.3.3 Journaling Apps</h4><p>Apps like <a href="http://www.thriveport.com/products/moodnotes/">Moodnotes</a> or <a href="http://www.moodtools.org/">Moodtools</a> focus on journaling as a technique to help depressed patients articulate their specific concerns and identify flaws in their logic or hyperbolic assumptions that can contribute to their negative mood. Clinical studies have shown journaling to be an effective way of managing mood levels and attitude for depressed patients.<a href="#_ftn6">[6]</a></p><p><em>Company Spotlight</em></p><p>The <a href="https://itunes.apple.com/us/app/stigma-journal-diary-mood-anxiety-tracker/id971950522?mt=8">Stigma</a> app takes a unique approach to augmenting the journaling process by building a word cloud to highlight the worst used most often when writing posts about your negative experiences. This can allow users to spot trends in their writing and reflect on the root causes of these emotions. The company has raised an undisclosed seed round from Slow Ventures.</p><h4>4.3.4 Game-Based — Therapy Apps</h4><p>A few teams are borrowing game mechanics to level-up patients in key skill areas to help them fight the symptoms of their depression.</p><p><em>Company Spotlight</em></p><p><a href="http://www.equoogame.com/">Equoo</a> is a mobile application that teaches players key psychological skills by guiding their character through a series of real-life challenges that can be solved with healthy mental health and physical habits. The game opened the Beta in Australia and New Zealand and has a weekly growth rate of 19% and a 4.8 rating in the app store. The company is based in the UK and has raised USD $0.4 million from angel investors and Indiegogo.</p><p><a href="https://www.superbetter.com/">SuperBetter</a> challenges users with quests to build four kinds of strength: social, emotional, mental, and psychical and was shown in a <a href="https://www.ncbi.nlm.nih.gov/pubmed/26182069">study by the University of Pennsylvania</a> to improve the moods of people who used the app for at least 30 days.</p><p><a href="https://www.happify.com/">Happify</a> is a self-improvement program that measures your baseline happiness and provides little tasks and games to help you increase it. The company is based in New York and has raised USD $25.6 million from TT Capital, Hills Capital, and Mangrove Capital amongst other investors.</p><h4>4.3.5 Chat-Based — Virtual Therapists</h4><p>Advances in Natural Language Processing (NLP) led to a much-hyped explosion of chatbots in 2017 with mixed results: we are somewhere between the Turing and the Singularity. However, simple developer-focused platforms from IBM, Microsoft, Facebook, and others allowed brands to experiment with virtual assistance through web and social channels. Teams have since taken these basic communication skills and encoded them with a psychologist skill set to offer psychotherapy services via chatbots.</p><p><em>Company Spotlight</em></p><p><a href="https://www.facebook.com/helloserenity/">Serenity</a> is an easy to use 24/7 CBT companion for depression, stress and anxiety that users can interact with via Facebook Messenger. The bot will perform daily check-ins and keep a log of the users’ mood so they can review their progress.</p><p><a href="http://www.woebot.io/">Woebot</a> offers a chatbot for emotional support and therapy with step-by-step guidance based on proven CBT methods in over 100 evidence-based lessons. The company has raised USD $8 million from New Enterprise Associates.</p><p><a href="https://www.shine.ie/">Shine</a> is a free service that sends out daily messages via text or Facebook with advice, positive reinforcement and motivational sayings. The company has raised USD $8.8 million from Comcast ventures, The New York Times, BBG Ventures, Betaworks, and others.</p><p><a href="https://www.wysa.io/">Wysa</a> is an AI-based ‘emotionally intelligent’ bot that claims to help users manage their emotions and thoughts through an array of tools and techniques such as evidence-based CBT, Dialectical Behavior Therapy (DBT), as well as guided meditation, breathing, and yoga. The company has raised USD $1.7 million from Kae Capital and others.</p><p><a href="https://www.hellojoy.ai/">Joy</a> takes a passive data collection approach by collecting the user’s physical activity, location and movement patterns in addition to social interactions, and self-reported mood and energy via its Facebook and Slack chatbots.</p><p><a href="https://www.x2ai.com/">Tess</a> is a chatbot built by clinical psychologists to coach people through tough times to build resilience, by having text conversations — similar to talking to a friend or coach, paid for by their employer.</p><p><strong><em>Investor Takeaway: We expect to see increasing investment in chat-based virtual therapists. Solutions that leverage non-text cues (i.e. Joy’s passive data collection) offer a way to make up for the lost information gathered by a traditional therapist by a person’s facial expressions, body language or voice inflections.</em></strong></p><h4>4.3.6 Chat-Based — Licensed Therapists</h4><p>Driven by the convenience of mobile, platforms have emerged that connect depressed patients with real psychologists to engage in a traditional therapy treatment via text and chat.</p><p><em>Company Spotlight</em></p><p><a href="https://www.talkspace.com/">Talkspace</a> first matches you with an available licensed therapist, then allows you to send messages (text, voice message, video message, or photo). The company was founded in 2011, is based in New York, and has raised USD $59.6 million from Qumra Capital, Norwest Venture Partners, Spark Capital, SoftBank Capital, and others.</p><p><a href="https://ginger.io/">Ginger.io</a> provides on-demand text coaching services and scheduled video sessions with licensed therapists and psychiatrists as part of an employer’s employee assistance program (EAP). Ginger.io’s customers include BuzzFeed and Pinterest and the company claims that up to 30% of a company’s employees will use the service once initiated. The company was spun out of the MIT Media Lab in 2010 and has raised USD $28 million from Kaiser Permanente Ventures, Khosla Ventures, True Ventures, and others.</p><h4>4.3.7 Chat-Based — Unlicensed Coaches</h4><p>Another approach to chat-based therapies has been to connect depressed patients to coaches, teachers, or other unlicensed professionals for more informal assistance — ostensibly trading professional designations for network scale and speed of response.</p><p><em>Company Spotlight</em></p><p><a href="https://joyable.com/">Joyable</a> is platform that matches patients with trained coaches to connect via phone, text, or email. The company has raised USD $15.1 million from Thrive Capital, Harrison Metal Capital, and the Collaborative Fund.</p><p><a href="https://www.7cups.com/">7 Cups</a> is a free, anonymous, confidential online text chat with trained listeners, online therapists and counselors that has facilitated over 29 million conversations. The company received USD $20,000 from Y Combinator as part of their summer 2013 batch.</p><p><a href="https://talklife.co/">TalkLife</a> is analogous to a <a href="http://whisper.sh/">Whisper</a> or (RIP) <a href="https://www.theverge.com/2017/4/28/15480052/yik-yak-shut-down-anonymous-messaging-app-square">Yik Yak</a> (which was once valued at USD $400 million) allowing users to post their mental health concerns and connect with other people who are suffering or eager to help. TalkLife is monitored by clinicians to spot dangerous comments or negative interactions. The company has raised $1.3 million from Leo Innovation Lab and Bethnal Green Ventures.</p><h4>4.3.8 Video-Based Medical &amp; Paramedical Therapists</h4><p>Telemedicine promises to transform the model and reach of modern healthcare professionals by expanding access to health services beyond physical limitations. Telemedicine startups have raised over $1.2B since 2013 including IPOs from market leaders like <a href="https://www.teladoc.com/">Teladoc</a> and <a href="http://www.telehealthcare.com/">Telehealthcare</a>.<a href="#_ftn7">[7]</a></p><p><em>Company Spotlight</em></p><p><a href="https://oncallhealth.ca/">Oncall Health</a> offers a PHIPA- and PIPEDA-compliant, encrypted video platform to major health clinics across Canada and the US. The company is based in Toronto and has raised an undisclosed seed round from Ripple Ventures.</p><p><a href="https://www.regrouptelehealth.com/">Regroup</a> offers a HIPAA-compliant video platform with end-to-end encryption for medical and psychiatric professionals to connect with their patients. The company has raised USD $14.5 million from OSF Ventures, Sandalphon Capital, and Frist Cressey Ventures.</p><p><a href="http://larkr.com/">LARKR</a> is focused explicitly on enabling mental health care professionals with matching algorithms that find therapists with the right experience to serve a patients specific needs and effortless, integrated billing. The company raised USD $100,000 in seed funding from undisclosed investors in March of 2017.</p><h3>4.4 Post-Treatment</h3><p>After completing a clinically supervised treatment program, patients now live with a very real understanding of what their unique experience of depression feels like and are hopefully armed with a set of skills to combat any future depressive episodes.</p><h4>4.4.1 Suicide watch Apps</h4><p>Most treatments for depression are episodic — helping the patients work through a specific experience and preparing them for life after treatment. Once they exit this highly supervised state, patients can feel somewhat isolated. A group of apps helps post-treatment patients build a plan if they ever experience strong suicidal feelings and are unable to access their traditional support network.</p><p><em>Company Spotlight</em></p><p><a href="http://my3app.org/">MY3</a> was designed for people who are depressed or suicidal, the app trains users to recognize suicide warning signs in themselves and others. MY3 prompts users to choose three close contacts that they would feel comfortable contacting when feeling particularly low.</p><h4>4.4.2 Mobile Time Monitoring Apps</h4><p>At their respective 2018 developer conferences, Apple announced <em>Screen Time</em> and Google showed off <em>Digital Wellbeing</em> — time monitoring applications built directly into their mobile operating systems to limit the time a user spends on their phone.<a href="#_ftn8">[8]</a> Each of the monitoring systems reports time spent in specific applications, allows users to set their own limits for each app, will notify the user when that time limit is exceeded and potentially lock them out of the app. These controls are extended for parents to monitor and lock application use on their children’s devices. Mobile time monitoring apps can be used by post-treatment patients to keep them from falling back into potentially destructive or deleterious habits once their traditional support phases out.</p><p><em>Company Spotlight</em></p><p><a href="https://inthemoment.io/">Moment</a> was founded in 2014 as a third-party application that monitors application use and allows users to set hard limits on screen time for themselves and their children. According to data from Pitchbook — the team has not raised venture capital financing.</p><h3>5.0 Summary</h3><p>How we decide to address mental health will have broad social, political, and economic implications that will shape large parts of industry and culture in coming decades.</p><p><strong>Part 1 Summary:</strong></p><p>Despite the unrelenting growth of global antidepressant prescriptions, there is insufficient evidence today to support the theory that technology addiction is causing a mass onslaught of depression, even amongst adolescents. However, we are encouraged by the mounting pile of research that suggests this link will be universally accepted by the scientific community in the coming years.</p><p><strong>Part 2 Summary:</strong></p><p>We believe that we are in the early days of investment and innovation driving positive patient outcomes using technology. The ability to deliver zero-marginal cost health care with equal, if not greater, predictive abilities than human therapists is an incredible compelling inevitability.</p><p>We believe there will be an emergent class of businesses that drive tremendous economic and social value over the next decade and are exited to partner with the entrepreneurs at the forefront of this movement.</p><p>If you are building in this space and would like to connect — please reach out by email to <a href="/service/mailto:mgoad@omersvenutres.com">mgoad@omersventures.com</a>.</p><h3>Sources</h3><p><a href="#_ftnref1">[1]</a> OMERS Ventures Analysis of data from Pitchbook.</p><p><a href="#_ftnref2">[2]</a> Meditation Programs for Psychological Stress and Wellbeing, Goyal et. al., Journal of the American Medical Association, 2014.</p><p><a href="#_ftnref3">[3]</a> Digital Voice Assistants: Platforms, Revenues &amp; Opportunities 2017–2022, Juniper Research, 2017.</p><p><a href="#_ftnref4">[4]</a> Models can more naturally detect depression in conversations, Rob Matheson, MIT News, 2018.</p><p><a href="#_ftnref5">[5]</a> Detecting Linguistic Traces of Depression in Topic-Restricted Text: Attending to Self-Stigmatized Depression with NLP, Wolohan et. al., Department of Information and Library Science Indiana University — Bloomington, 2018.</p><p><a href="#_ftnref6">[6]</a> Ten ways to improve the treatment of depression and anxiety in adults, Dunlop et. al., Mental Health in Family Medicine Journal, 2013.</p><p><a href="#_ftnref7">[7]</a> Telemedicine Startup Funding, CB Insights, 2017.</p><p><a href="#_ftnref8">[8]</a> How do Apple’s Screen Time and Google Digital Wellbeing stack up?, Chaim Gartenberg, The Verge, 2018.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2e03ca752b8d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Current State of Depression]]></title>
            <link>https://medium.com/@markjgoad/the-current-state-of-depression-f0604393c78e?source=rss-d9ca5d9d52a0------2</link>
            <guid isPermaLink="false">https://medium.com/p/f0604393c78e</guid>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[depression]]></category>
            <category><![CDATA[investing]]></category>
            <dc:creator><![CDATA[Mark Goad]]></dc:creator>
            <pubDate>Fri, 01 Feb 2019 15:52:26 GMT</pubDate>
            <atom:updated>2019-02-01T16:11:04.063Z</atom:updated>
            <content:encoded><![CDATA[<h3><strong>Part 1 of 2</strong></h3><p><em>A two-part report on the global depressed population; the role of technology in causing depression; and a VC’s investment framework for solutions.</em></p><p><strong>Part 1</strong> looks past the current hype (read: media coverage) around depression to primary census data to understand if there are structural changes in the global depressed population over the last 20–60 years (country/data dependent).</p><p><a href="https://medium.com/@goader92/the-current-state-of-depression-2e03ca752b8d"><strong>Part 2</strong></a><strong> </strong>proposes OMERS Ventures’ investment framework and looks at interesting startups across the life-cycle of care for depressed patients.</p><p>Special thanks to the leadership team at <a href="https://medium.com/u/1b8d4a5567c9">OMERS Ventures</a> who supported me with time, intros, and resources to pull together this research over the past few months.</p><h3>0.0 Introduction</h3><p>We chose to look specifically at depression (not mental health more broadly) because of the scale and severity of the disease.</p><p>Per the World Health Organization, depression is the most common illness in the world and the leading cause of disability, affecting 300 million people every year.<a href="#_ftn1">[1]</a> Today in Canada, 500,000 people are unable to work due to mental health problems.<a href="#_ftn3">[2]</a></p><p>Depression is inextricably tied to suicide, which will be the leading global cause of death for people under 18, behind only HIV and AIDS, by 2020. This mirrors the Canadian reality: suicide is the second leading cause of death for young adults, accounting for almost one quarter of all deaths.<a href="#_ftn4">[3]</a> Globally, two people kill themselves every minute.</p><h3><strong>We wanted to understand if the current hype (read: media coverage) over depression is justified by a recent surge in diagnoses or if baseline rates of clinical depression have remained unchanged.</strong></h3><p>To answer this question, we performed a systematic review of academic journals covering depression in the United States, Canada, the UK, and other developed economies. Additionally, we conducted a meta-analysis of primary surveys (mostly census data) to map out the rates of depression over the past 60 years in Canada and the US. Key questions we asked include:</p><h4>· What is the definition of depression? To what degree does sadness play a role in depression?</h4><h4>· How do we measure depression? Are we more depressed today than in past decades?</h4><h4>· Are we over-diagnosing depression? Are we over-prescribing antidepressants?</h4><p>Our review of primary data from the World Health Organization, Statistics Canada, and the U.S. Centers for Disease Control and Prevention reveals an observable, <strong>but</strong> <strong>not a watershed</strong> <strong>or exponential,</strong> increase in the number of depressed individuals globally over the past two decades. In fact, the only structural change is the <strong>number of people taking antidepressants</strong>, which has increased nearly 10x faster than the rates of depression diagnoses in OECD countries. There is a litany of reasons why antidepressants are on the rise globally, including cultural, societal, and commercial influences.</p><p>Next, we looked at over a decade worth of evidence linking our increasing use of technology to reports of increased anxiety and depression, especially among younger users. While troubling, <strong>the data available today is unable to draw a direct connection between the increased use of technology and an increasing incidence of clinical depression</strong>. However, there is strong evidence to believe that this connection will be established within the next decade of research.</p><p>Finally, we review the funding ecosystem for solutions that leverage technology to help patients suffering from depression. Specifically, we built a value-based framework to categorize solutions along the lifecycle of patient care: pre-diagnosis, diagnosis, treatment, and post-treatment.</p><p>In this piece, we assess technology as both a contributor to and a potential mitigant for modern depression. The duality of this perspective borrows from Professor Kentaro Toyama, a W. K. Kellogg Associate Professor at the University of Michigan School of Information, and his “law of amplification” which states technology is merely a lever which enhances human intent, whether it be malice or benevolence.</p><p>History offers clear examples of the dichotomy of technology amplification: high-capacity automatic rifles protect and harm, social media enables both philanthropy and the alt-right.</p><h3>1.0 Defining Depression and its Costs</h3><p>Depression has been written about for over 4,000 years, with the Mesopotamians describing the negativity experienced by those possessed by demons. The Greek physician Hippocrates wrote about ‘melancholia’ in 420 B.C. as a clinical syndrome caused by a chemical imbalance of human body fluids, specifically an excess of black bile in the spleen. Hippocrates prescribed treatments included bloodletting, baths, exercise, and diet.<a href="#_ftn5">[4]</a> Our understanding of the cause of depression has evolved from spiritual and emotional to biophysical and neurochemical and consequentially treatment has moved beyond torture and exile to psychological and pharmacological remedies.</p><p>Today, researchers <em>generally</em> agree that there are many causes of depression, including structural differences in brain composition and neurotransmitter levels, inherited traits from genetics, and stressful or traumatic life events.<a href="#_ftn6">[5]</a> It is believed that several of these forces interact to bring on depression. Biochemically, depression can be brought on by imbalances in brain chemistry, specifically the neurotransmitters serotonin and noradrenaline, or brain composition, specifically an overactive or inflamed amygdala, prefrontal cortex, hippocampus, or related limbic system components.<a href="#_ftn7">[6]</a></p><p>The definitive guide for medical practitioners is the fourth version of the Diagnostic and Statistical Manual (DSM-IV) of Mental Disorders which defines an episode of major depressive disorder (MDD) as <strong>at least two weeks</strong> of a depressed mood as well as at least five other symptoms, such as:</p><p>• Sleep issues (either difficulty sleeping or sleeping too much);</p><p>• Changes in appetite and weight (delta of more than 5 percent body weight in a month);</p><p>• Decreased energy or fatigue almost every day;</p><p>• Difficulty concentrating, making decisions, and thinking clearly almost every day;</p><p>• Recurrent thoughts of death or suicide, a suicide attempt, or a specific plan for suicide.</p><p>What should be strikingly evident from the list of symptoms above is that, beyond suicide, these ailments sit on the same spectrum of sadness that all humans have experienced for millennia. This ambiguity makes it difficult to accurately diagnose depression at scale while simultaneously perpetuating the modern stigma of the disease.</p><h3>Specifically, it is<strong> difficult to ascertain who is exaggerating and who is mentally ill </strong>— even for those who are themselves suffering<strong>.</strong></h3><p>Laying on the other side of this ambiguity is the crippling global cost of untreated depression. Globally, studies have calculated the direct (i.e. healthcare, medication, psychiatry visits, etc.) and indirect costs (i.e. loss of productivity, income losses, etc.) to amount to USD $2.5 trillion per year. I personally hate the hyperbolism of global cost claims — but digging into these numbers reveal some very real hard dollars.</p><p>For business leaders, the most powerful statistic is that people suffering from depression miss, on average, 25 days of regular activity because of their symptoms, this includes work and important events. A startup of 100 people in Canada, where 5.4% of the population is clinically diagnosed with depression, could lose up to 125 working days per year because of depression.<a href="#_ftn8">[7]</a></p><h3>1.1 Diagnosing Depression: Self-Reporting &amp; Clinical Reporting</h3><p>Due to the intrinsic ambiguity of diagnosing depression as a severe, prolonged form of sadness — there remain significant barriers to accurately measuring the size of the global depressed population.</p><p>The self-diagnosis of depression is not based on the absolute severity of symptoms but by that patient’s interpretation of the severity of their symptoms relative to the imagined pain of others.<a href="#_ftn9">[8]</a></p><h3>From this perspective,<strong> depression is an experience that is relative to the sadness we imagine others feel, not an absolutely value or measure we can easily quantify.</strong></h3><p>This is probably the greatest driver of the “everyone is sad, just suck it up” stigma around depression that is slowly eroding. The World Health Organization estimates that fewer than 50% of those affected in the world (and in many countries, fewer than 10%) seek treatment for depression.<a href="#_ftn10">[9]</a> In the U.S., the Centers for Disease Control and Prevention (CDC) reports that only 35% of patients with severe depressive symptoms had seen a mental health professional in the past year.<a href="#_ftn11">[10]</a></p><p>The ambiguity inherent in self-reporting depression can be partially reduced once that patient engages a medical professional. While waiting for a patient to find a medical professional introduces survivorship bias (it is more likely a patient is truly ill if they are willing to accept medical help) it allows for a more concrete diagnosis of depression using a standardized patient survey.</p><p>Figure 1 illustrates how clinically depressed patients, with either mild, moderate or severe depression, experience key cognitive manifestations of depression far more frequently than non-depressed individuals.<a href="#_ftn12">[11]</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/583/1*ijnHrRGFqJdlJtQMPn3NxQ.png" /></figure><h3>1.2 Are We More Depressed Today than in the Past?</h3><p>Using the definition of depression set out in the DSM-IV as the incidence of psychological trauma over a period of at least two weeks, we looked for studies which used consistent definitions and questions over a multi-year or multi-decade time horizon.</p><p>Figure 2 shows the number of US adults who experienced a serious psychological distress in the past 30 days with data spanning 1997 to 2017.<a href="#_ftn13">[12]</a> Over the past 21 years, the incidence of serious psychological distress has not structurally changed for adults in the United States.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/624/1*WlkI05D-yRI50JoG-B5UXQ.png" /></figure><p>Looking at psychological distress in young adults in the US, aged 12 to 17, tells a different story.</p><p>From 2006 to 2014, observations by the US Department of Health &amp; Human Services of major depressive episodes in the past year increased by 41.3%, an average annual increase of 4.6%.<a href="#_ftn14">[13]</a> This increase persisted even after researchers adjusted for substance abuse disorders and sociodemographic factors.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/624/1*0KnrsHyv_NQ5rq6kgwSTRA.png" /></figure><p>Following the troubling trend seen among the youth, the age-adjusted suicide rate in the United States increased 26.1%, or 1.8% per year from 1999 through 2014. The percent increase in suicide rates for females was greatest for those aged 10 to 14, and for older males aged 45 to 64.<a href="#_ftn15">[14]</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/624/1*ZS2zZcDZnhOJu9-C2LoNeg.png" /></figure><p>In summary, the primary data from the U.S. does suggest an increase in the number of depressed and suicidal, particularly for young adults, but not an exponential or structural change in this population.</p><p>In Canada, to attempt to gain a broader, historical view of the prevalence of depression, we performed a meta-analysis (combining data from different research studies) by merging five separate surveys that provide the 12-month prevalence of a major depressive episode (MDE) from 1952 to 2012.<a href="#_ftn16">[15]</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/624/1*Fy3vxlI7DmkkqK-RA_s4WQ.png" /></figure><h3>These studies span 60 years of Canadian mental health history and record a strikingly consistent message across those six decades: the rate of depression in Canada has remained remarkably consistent since 1952.[16] [17]</h3><p>In fact, of 22 data observations across five studies, only four fall outside the range of 4.5% to 6.0%. Put another way, the average standard deviation for years with multiple records was only 0.2% across all years. These results were consistent with third party studies which also found that the prevalence of clinically diagnosed depression and distress has remained generally stable among Canadians over the past 15 years at around 5%.<a href="#_ftn19">[18]</a></p><p>Globally, particularly in developing nations, the sparsity of survey data makes multi-decade clinical studies nearly impossible. The World Health Organization’s Department of Mental Health notes that the rate of people suffering globally from depression currently is one in twenty, mirroring the Canadian rate of 5%.<a href="#_ftn20">[19]</a></p><h3>1.3 Are we Overly Prescribing Antidepressants?</h3><p>Antidepressants are medications that help relieve the symptoms of depression, anxiety, and related mental health conditions. The most common antidepressants are selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). SSRIs block the “reuptake” or absorption of serotonin, which is known as the ‘happy chemical’, thereby stabilizing the patient’s mood. SNRIs block the reuptake of serotonin and norepinephrine — a related neurotransmitter associated with happiness.</p><p>One of the most interesting and complex debates in health today is whether patients are over-prescribed antidepressants. On the one hand, organizations like the World Health Organization claim that the treatment rate for depression is well below 10% in many countries.<a href="#_ftn21">[20]</a> Contrarily, the OECD Health indicator report shows that the number of people taking antidepressants in OECD countries <strong>increased by 145.2% between 2000 and 2015, representing a 9.7% average annual increase</strong>. The Czech Republic, Slovakia, and Estonia saw total increases of over 200% during this fifteen-year period.<a href="#_ftn22">[21]</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/620/1*w7AEgEP27GbbQwtqLP3YTQ.png" /></figure><p>The OECD report notes that the increase in the use of anti-depressants can be explained by a number of factors, including the improved recognition of depression, better access to mental health care, changes in patient or provider attitudes due to fading stigma, as well as anti-depressants being used to treat ailments other than depression, including anxiety, obsessive compulsive disorder, and related disorders. Other researchers have argued that mental health professionals have used a definition of depression that conflates genuine depression with intense, but normal, sadness which has led to the over-prescription of antidepressants.<a href="#_ftn23">[22]</a> The reality is that we cannot discern the exact reason why 9% of Canadians consume anti-depressants while only 5% are clinically diagnosed with depression. Nor was it our goal to draw conclusions about these discrepancies.</p><h3>Regardless of the cause, we can conclude from this primary data that <strong>the drastic increase in antidepressant prescriptions over the last 15 years is not tied to a similar or proportionate increase in the incidence of depression, namely severe psychological distress, over the same period</strong>.</h3><p>This conclusion has been replicated in other primary data analyses studies in the UK, USA, Canada, and Australia over the past two decades.[23]</p><p>For OMERS Ventures, the truth of whether or not patients were previously under-prescribed or are currently over-prescribed is unquestionably out of reach for our organization. However, our organization is uniquely positioned to act on the following conclusions of our research:</p><p>1. More people (especially the young) around the world are suffering from depression;</p><p>2. A lot more people are seeking clinical (i.e. pharmacological) solutions for mental health and related ailments;</p><p>3. There is a visceral disagreement as to whether existing pharmacological solutions (i.e. drugs) are the right solution.</p><p>Ah — opportunity.</p><p>We could look at the general distain towards antidepressants, which is largely driven by the view that the increase in their consumption is a product of the pharmaceutical-industrial complex, as an opportunity for non-drug solutions to be accepted by a somewhat skeptical, younger, consumer-patient base.</p><p>As a technology investment fund, our next step is to dive into emerging research that shows a link between technology use and depression, before determining whether technology can be used as a tool to alleviate the symptoms of those suffering.</p><h3>2.0 The Role of Technology in the Modern Depressed Population</h3><p>There is rampant public speculation that the increasing use of technology is <strong>causing mass isolation and depression</strong> — especially among young adults. Recent articles from <a href="https://www.forbes.com/sites/robertglatter/2018/04/13/digital-addiction-a-recipe-for-isolation-depression-and-anxiety/#250d24dd5f6b">Forbes</a>, <a href="https://www.cnn.com/2017/11/30/health/smartphone-addiction-study/index.html">CNN</a>, <a href="https://www.independent.co.uk/life-style/gadgets-and-tech/news/smartphone-internet-addiction-phone-imbalance-brain-anxiety-tiredness-study-research-a8084146.html">The Independent</a>, <a href="https://www.sciencedaily.com/releases/2016/03/160302121325.htm">Science Daily</a>, and others reference studies of what is broadly referred to as “technology addiction”, the obsessive use of both hardware (i.e. mobile, tablets, gaming consoles) and software (i.e. messaging, social networks, mobile games, new media [YouTube, Snapchat, etc.]).</p><p>The difficulty with establishing a connection between technology addiction and a structural change in depression rates is that spot studies show self-reported feelings of “isolation” or “depressed mood” — and however troubling these data might be — they are often dismissed for not meeting the DSM-IV standard for clinical depression.</p><p>In this section, we lay out the basic construct of the argument which suggests a connection between technology addiction and depression and discuss where we expect this debate to evolve with future research.</p><p>The argument supporting technology addiction is generally based on the assertion that “things are changing faster than ever”. This platitude is driven by the global adoption of technology over the past decade; perhaps best illustrated by the rate at which we adopted modern social networks over the past few years, shown below. <a href="#_ftn25">[24]</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/614/1*1KycFBmNk15Ve96qxC_STg.png" /></figure><p>We can see the implications of this trend in the number of hours spent with digital media which has increased by 122% over the past decade.<a href="#_ftn26">[25]</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/605/1*FDjy1iPQUC7gMHJK6FFnxQ.png" /></figure><p>This massive change in the way humans spend 1/3 of their waking hours (dare I say ‘woke’ hours) has not gone unnoticed. Researchers have invested a significant amount of time and energy to try to solidify a link between this new behavior and negative effects on the modern human psyche, especially amongst young adults.</p><p>Specifically, researchers have shown that adolescents, aged 13 to 18, who spend more time on social media and smartphones are more likely to report mental health issues than adolescents who spend more time on non-screen activities, even when controlling for cyclical factors like the state of the broader economy.<a href="#_ftn27">[26]</a> Additional research targeted at Facebook shows that a 1-standard-deviation increase in activity on the social network results in a 8% decrease in self-reported mental health.<a href="#_ftn28">[27]</a> Another 2016 peer-reviewed study showed that Facebook users had significantly lower life satisfaction than non-users.<a href="#_ftn29">[28]</a></p><p>Importantly, these researchers admit that there is no way to determine the nature of the relationship — perhaps adolescents who are depressed seek refuge in online communities and new media. In fact, the last study from 2016 noted that the deleterious effects of Facebook were most pronounced in users who were passively using the product — defined as just surfing through and consuming content — while users who were actively contributing, connecting, and engaging with others on Facebook had an <strong>increase in life satisfaction compared to non-users</strong>. This directly supports our perspective of technology as an amplifier of both positive and negative human experiences.</p><p>In general, these modern studies of technology addiction and depression suffer from a lack of direct causality between a specific activity and the medical consequence.</p><h3>This persistent ambiguity is shockingly similar to the challenges faced by scientists who sought to establish a link between cigarette smoking and respiratory disease.</h3><p>Centuries ago, smoking tobacco was used a remedy for infected wounds, headaches and colds. Starting their work in the 1950s, it took researchers decades to accumulate a critical mass of data to reach scientific consensus around the harms of smoking.<a href="#_ftn30">[29]</a> In this vein, we expect to see further lobbying and academic research activities by large technology companies with a vested interest in the continued use of their products, seeking to influence the scientific consensus — likely taking the form of spot surveys or anecdotes (i.e. look how much our tech helped this person). We will continue to look to large, multi-decade, cross-sectional studies for the true impact of technology on incidence of clinical depression.</p><p>Beyond the ambiguity of direct attribution, the other difficulty with establishing causality is that <strong>technology can absolutely be used to improve our mental health.</strong> Online communities create opportunities for engagement beyond physical or geographic boundaries; virtual cyber-psychologists have zero marginal cost and can be universally accessible.</p><p>Studies like the one conducted by mobile time management app Moment help illustrate the incredible dichotomy that can exist between happy users who like checking-in on an app and unhappy users who are addicted to the technology. <a href="#_ftn31">[30]</a><a href="#_ftn32">[31]</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/624/1*yyu55Qbvh2QhT8CcmZFKBw.png" /></figure><p>Moving forward, we expect to see mounting evidence of a causal link between technology use and depression, especially among young adults in developed countries.</p><p>Check out <a href="https://medium.com/@goader92/the-current-state-of-depression-2e03ca752b8d"><strong>Part 2</strong></a> for an overview of the landscape of technology companies addressing the patient life-cycle of depression.</p><h3>Sources</h3><p><a href="#_ftnref1">[1]</a> Depression Fact Sheet, World Health Organization, March 2018.</p><p><a href="#_ftnref3">[2]</a> Mental Health Matters, Mental Health Commission of Canada, 2018.</p><p><a href="#_ftnref4">[3]</a> Depression and suicidal ideation among Canadians aged 15 to 24, Leanne Findlay, Statistics Canada, 2017.</p><p><a href="#_ftnref5">[4]</a> The History of Depression: Accounts, Treatments, and Beliefs through the Ages, VeryWellMind, 2018.</p><p><a href="#_ftnref6">[5]</a> What Causes Depression, Harvard Medical School Journal, 2009.</p><p><a href="#_ftnref7">[6]</a> Major Depression: Causes or Effects? Alan F. Schatzberg , M.D., The American Journal of Psychiatry, 2002.</p><p><a href="#_ftnref8">[7]</a> Depression in Canada, Public Health Agency of Canada: Chronic Diseases — Mental Illness, 2016.</p><p><a href="#_ftnref9">[8]</a> Am I Abnormal? Relative rank and social norm effects in judgements of anxiety and depression symptom severity, Karen Melrose and Alex Wood, Journal of Behavioral Decision Making, Volume 26, 2012.</p><p><a href="#_ftnref10">[9]</a> Depression Fact Sheet, World Health Organization, March 2018.</p><p><a href="#_ftnref11">[10]</a> Depression in the U.S. Household Population, 2009–2012, Centers for Disease Control and Prevention, 2014.</p><p><a href="#_ftnref12">[1</a>1] Depression: Causes and Treatments, Aaron T. Beck, M.D. and Brad A. Alford, University of Pennsylvania Press, 2009.</p><p><a href="#_ftnref13">[12]</a> National Health Interview Survey, 1997-March 2017, National Center for Health Statistics, 2017.</p><p><a href="#_ftnref14">[13]</a> National Trends in the Prevalence and Treatment of Depression in Adolescents and Young Adults, Ramin Mojtabai, MD, PhD, MPH, Mark Olfson, MD, MPH, Beth Han, MD, PhD, MPHe, PEDIATRICS Volume 138, 2016.</p><p><a href="#_ftnref15">[14]</a> Increase in Suicide in the United States, 1999–2014, Centers for Disease Control and Prevention, 2014.</p><p><a href="#_ftnref16">[15]</a> DPAX 1 = “Depression and Anxiety Questionnaire 1“; DPAX 2 = “Depression and Anxiety Questionnaire 2“; DIS = “Diagnostic Interview Schedule“; NPHS = “National Population Health Survey”; CCHS;MH = “Canadian Community Health Survey — Mental Health”</p><p><a href="#_ftnref17">[16]</a> A 40 Year Perspective on the Prevalence of Depression: The Stirling County Study; Murphy et. al., The Archives of General Psychiatry, 2000.</p><p><a href="#_ftnref18">[17]</a> The Prevalence of Major Depression is Not Changing; Patten et. al., Canadian Journal of Psychiatry, 2015.</p><p><a href="#_ftnref19">[18]</a> Is mental health in the Canadian population changing over time? Simpson et. al, Canadian Journal of Psychiatry, May 2012.</p><p><a href="#_ftnref20">[19]</a> Depression Largest Cause of Disability Worldwide, World Health Organization, 2017.</p><p><a href="#_ftnref21">[20]</a> Depression Fact Sheet, World Health Organization, March 2018.</p><p><a href="#_ftnref22">[21]</a> Health at a Glance, OECD Indicators, 2017.</p><p><a href="#_ftnref23">[22]</a> The Loss of Sadness; How Psychiatry Transformed Normal Sorrow into Depressive Disorder, Allan Horwitz and Jerome Wakefield, 2007.</p><p><a href="#_ftnref24">[23]</a> National patterns in antidepressant medication treatment. Olfson M, Marcus SC., Archives of General Psychiatry, 2009.</p><p>National trends in long-term use of antidepressant medications: results from the US National Health and Nutrition Examination Survey, Mojtabai R, Olfson M., Journal of Clinical Psychiatry, 2014.</p><p>Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010, Ilyas S, Moncrieff J., British Journal of Psychiatry, 2012.</p><p>Trends in primary care antidepressant prescribing 1995–2007: a longitudinal population database analysis, Lockhart P, Guthrie B., British Journal of General Practice, 2011.</p><p>Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study, Noordam R, et al., European Journal of Clinical Pharmacology, 2015.</p><p>Trends in the dispensation of antidepressant drugs over the past decade (2000–2010) in Andalusia, Spain, González-López M, et al., Social Psychiatry and Epidemiology, 2015.</p><p>Increase in the duration of antidepressant treatment from 1994 to 2003: a nationwide population-based study from Finland, Sihvo S, et al., Pharmacoepidemiology and Drug Safety, 2010.</p><p>Incidence and determinants of long-term use of antidepressants, Meijer WE, et al., European Journal of Clinical Pharmacology, 2004.</p><p>Antidepressant dispensing trends in New Zealand between 2004 and 2007, Exeter D, Robinson E, Wheeler A., Australia New Zealand Journal of Psychiatry. 2009.</p><p>Antidepressant utilization in British Columbia from 1996 to 2004: increasing prevalence but not incidence, Raymond CB, Morgan SG, Caetano PA, Psychiatry Serv, 2007.</p><p><a href="#_ftnref25">[24]</a> Number of Social Network Users Worldwide from 2010 to 2021, eMartketer, 2018.</p><p><a href="#_ftnref26">[25]</a> Daily Hours Spent with Digital Media per Adult User, eMarketer, 2017.</p><p><a href="#_ftnref27">[26]</a> Increases in Depressive Symptoms, Suicide-Related Outcomes, and Suicide Rates Among U.S. Adolescents After 2020 and Links to Increased New Media Screen Time, Twenge et. al., Clinical Psychological Science, 2018.</p><p><a href="#_ftnref28">[27]</a> Association of Facebook Use with Compromised Well-Being: A Longitudinal Study, Shakya HB and Christakis NA, American Journal of Epidemiology, 2017.</p><p><a href="#_ftnref29">[28]</a> The Facebook Experiment: Quitting Facebook Leads to higher Levels of Well-Being, Morten Tromholt, Cyberpsychology, Behavior and Social Networking, 2016.</p><p><a href="#_ftnref30">[29]</a> Inventing Conflicts of Interest: A History of Tobacco Industry Tactics, Allan Brandt PhD., American Journal of Public Health, 2012.</p><p><a href="#_ftnref31">[30]</a> Moment is a time management mobile application that tracks how much time you spend using specific apps on your phone and provides analytics, insights, notifications, and locks to help you reduce smartphone dependence.</p><p><a href="#_ftnref32">[31]</a> How heavy use of social media is linked to mental illness, The Economist, 2018.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f0604393c78e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Video games are not “just a hits business” — an investor’s guide]]></title>
            <link>https://medium.com/@markjgoad/video-games-are-not-just-a-hits-business-an-investors-guide-f4c0da80f1e0?source=rss-d9ca5d9d52a0------2</link>
            <guid isPermaLink="false">https://medium.com/p/f4c0da80f1e0</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[esport]]></category>
            <category><![CDATA[investing]]></category>
            <dc:creator><![CDATA[Mark Goad]]></dc:creator>
            <pubDate>Mon, 01 Oct 2018 11:55:45 GMT</pubDate>
            <atom:updated>2018-10-01T14:18:00.767Z</atom:updated>
            <content:encoded><![CDATA[<p>I believe there is an inaccurate framing of the video game industry as “<strong><em>just a hits-driven business</em></strong>”. While ‘hit’ games have always been an important part of the industry — video games and eSports have evolved into a diverse ecosystem for which investors need a new framework to assess opportunities.</p><p>You should read this piece if you are interested in deconstructing the current hype around video games and eSports that has seen <strong>billions of dollars of investment </strong>from <a href="http://www.chicagotribune.com/sports/breaking/ct-esports-robert-kraft-nfl-nba-nhl-mlb-owners-20180117-story.html">traditional sports teams</a>, <a href="http://www.nba.com/article/2018/04/09/morning-tip-nba-2k-league-draft-serious-business-players-owners-fans">traditional sports leagues</a>, <a href="https://www.alistdaily.com/strategy/these-traditional-sports-players-are-taking-on-esports/">professional athletes</a>, <a href="https://www.forbes.com/sites/alexknapp/2017/04/18/the-midas-list-venture-capitalists-investing-in-video-games/#565dde382dd4">venture capitalists</a>, <a href="https://esportbet.com/athlete-and-celebrity-investors/">pop stars</a>, <a href="https://www.bloomberg.com/news/articles/2017-05-24/silver-lake-invests-400-million-in-video-game-toolmaker-unity">private-equity firms</a>, <a href="http://www.espn.com/esports/story/_/id/20851460/marshawn-lynch-rod-part-15-million-investment-round-nrg-esports">media moguls</a>, <a href="https://www.businessinsider.com/top-esports-sponsors-gaming-sponsorships-2018-1">Fortune 100 corporates</a>, and a diverse array of <a href="https://www.fool.com/investing/general/2013/09/28/gta-5-sales-hit-1-billion.aspx">game publishers</a> over the past few years.</p><p>I am not writing from the perspective of a professional gamer, although I did play in a few semi-pro Halo tournaments back in the day. <strong>Somewhat counter-intuitively, twenty years of <em>weekly </em>video game play was less valuable than a fundamental understanding of how multi-sided businesses function across social networks, traditional sports leagues, advertising platforms, and enterprise SaaS startups.</strong></p><p>Key trends discussed:</p><ul><li>The globalization and professionalization of video games;</li><li>The rise and consequences of cross-platform play;</li><li>eSports’ transition from tournaments to league play;</li><li>How cloud technology has influenced game distribution &amp; consumption;</li><li>Emerging enterprise software ecosystems.</li></ul><blockquote>Readers Note: investor takeaways will be denoted in this format.</blockquote><h3>To start, I propose a 10 level, value-based framework to categorize investment from Platform to Player:</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IiD-iMDxVVhVQmpEB8c4Tw.png" /><figcaption>Video Game Industry: Investor Framework (September 2018)</figcaption></figure><p>The framework combines aspects of the video game industry with the eSports industry in an attempt to categorize every business that I have come across over the past few months of research. While most industry players focus on one tier within the framework — an excellent example of vertical integration is <a href="https://twitter.com/Microsoft?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor">Microsoft</a>, shown on the right-hand side in green.</p><p>Microsoft owns the platform (Windows and Xbox), distribution (Windows Store and Xbox Games Store), game engines (Microsoft Direct), game developers (they have acquired <a href="https://techcrunch.com/2018/06/10/microsoft-acquires-a-whole-bunch-of-game-studios/">numerous studios</a> to make certain titles only available on Xbox), games (Microsoft’s Minecraft and Halo are two of the largest game franchises in history), eSports teams (<a href="https://valiant.overwatchleague.com/en-us/news/la-valiant-and-immortals-partner-microsoft-community-events-aimed-growing-esports-ecosystem">sponsoring</a> <a href="https://valiant.overwatchleague.com/en-us">LA Valiant</a> of the <a href="https://overwatchleague.com/en-us/">Overwatch League</a>), pro-level accessories (ex: <a href="https://www.xbox.com/en-CA/xbox-one/accessories/controllers/elite-wireless-controller">CAD $189 Xbox Elite controllers</a>), and video game broadcasting service <a href="https://mixer.com/">Mixer</a> (acquired as Beam in 2016).</p><p>While Microsoft is a great example of vertical integration across the stack, their portfolio hardly scratches the service of emerging investment opportunities — so let’s jump in ⤵️.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/450/0*Rh2ntYT3sB0rmuoK.jpg" /></figure><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>[loading]</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p>.</p><p><strong>Level 1: Audience &amp; Casual Players</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*jO7unAyYl9dO5A9f3oFohw.png" /><figcaption>Level 1</figcaption></figure><p><a href="https://www.statista.com/statistics/748044/number-video-gamers-world/"><strong>2.2 billion people</strong></a><strong> </strong>played a mobile, console, PC, handheld, or virtual reality game in 2017. That’s a lot.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/571/1*I0oKG3ZH50ku2oMd1CMXLw.png" /><figcaption>Number of active video gamers worldwide, 2014–2021</figcaption></figure><p>The focus of the piece will be on what is known as the ‘core gaming’ segment — namely PC and console gaming — where almost all eSports activity occurs today.</p><p>Understanding the gamer persona is important to understand the value of these platforms for advertisers. While overly simplistic, the click-bait proclamations of <strong><em>“gamers are older and more female than you think”</em></strong> are true. More women are interested in video games as they graduate from pervasive mobile games into core gaming segments. As an example, the percentage of women PC gamers in the US has risen steadily from 28% in 2003 to 48% in 2014.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/520/1*VL_vM8GrwUNvtjQ-qYfe1g.png" /><figcaption>% of Male vs. Female Core Video Gamers</figcaption></figure><p>Unsurprisingly, a generation of young, Red Bull-fueled men did not take this perceived ‘invasion’ (cultural metaphor intended) without a characteristically immature reaction which culminated in the horrific 2014 <a href="https://en.wikipedia.org/wiki/Gamergate_controversy">#GamerGate</a> saga and is the basis for modern Twitch star <a href="https://www.theverge.com/2018/8/14/17688392/ninja-fortnite-women-streaming-harassment">Ninja’s policy of not streaming with women gamers</a>. While this history is not directly related to early-stage technology investors — it is important context of an industry still struggling to mature.</p><p>Despite this hostility, core gamers are on average 30 years old and earn a well-above-average USD $90k, making them a key demographic for most advertisers.</p><p><strong>Audience</strong></p><p>Stop asking the young person in your office “why do you like watching other people play video games?”.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*rrv-ZeX30PWBWxY4YkDBLQ.png" /><figcaption>Ninja’s Twitch Stream</figcaption></figure><h3>Watching video games is better than watching traditional sports.</h3><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fgiphy.com%2Fembed%2F1tzOBPH5K7qOQ%2Ftwitter%2Fiframe&amp;url=https%3A%2F%2Fmedia.giphy.com%2Fmedia%2F1tzOBPH5K7qOQ%2Fgiphy.gif&amp;image=https%3A%2F%2Fmedia.giphy.com%2Fmedia%2F1tzOBPH5K7qOQ%2Fgiphy-downsized-large.gif&amp;key=a19fcc184b9711e1b4764040d3dc5c07&amp;type=text%2Fhtml&amp;schema=giphy" width="435" height="244" frameborder="0" scrolling="no"><a href="https://medium.com/media/06c557bf73a30e68b26a358cfc1c7383/href">https://medium.com/media/06c557bf73a30e68b26a358cfc1c7383/href</a></iframe><p>Professional gamers spend <a href="https://www.polygon.com/2018/4/24/17274636/ninja-fortnite-twitch-h3h3-podcast">+100 hours/week playing their sport</a>. Their skill, speed, and accuracy is incredible to watch.</p><p>Moreover, modern video game streaming platforms are magnitudes more immersive than traditional sports broadcasting. Not only can I watch a game unfold from the exact same view as my favorite player, I can watch a live video feed of their face and hands to see their expressions and lightning quick reactions in gameplay. I can hear their commentary explaining their strategy in real time, listen to their terrible insults, and feel their frustration when things go wrong. Further, I can interact with these global superstars and other fans in the chat window — and if I’m lucky — they might even read out my question and answer it in the middle of their stream.</p><h4>^This is far more engaging than the traditional sports viewing experience.</h4><p>In fact, the top ten video games had <strong>591.4 million</strong> unique viewers in LTM August 2017 — more than the <strong><em>combined </em></strong>global audiences of:</p><ul><li>HBO — 142 million</li><li>ESPN — 115 million</li><li>Netflix — 100 million</li><li>Hulu — 12 million</li></ul><p>Fortnite’s <strong><em>unofficial </em></strong>#FridayFortnite challenge started by a YouTuber reached 8.8 million unique viewers alone — more than:</p><ul><li>The season finale of AMC’s “The Walking Dead” (7.9 million)</li><li>The first round of the NFL draft (5.3 million)</li><li>The season premier of HBO’s “Westworld” (2.1 million)</li></ul><blockquote>Investor Takeaway: you already knew video games were “big” — but the relative scale and engagement to traditional media is shocking for most.</blockquote><p><strong>Level 2: Broadcasting, Community, Betting</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*eHakweHToInIhK4Szep08w.png" /><figcaption>Level 2</figcaption></figure><p>A layer of consumer-facing businesses has emerged at the intersection of audiences and players to facilitate interaction, engagement, and of course, gambling.</p><p>From an investor standpoint — the major viewing platforms are largely solidified with <a href="https://www.twitch.tv/">Twitch</a> (<a href="https://techcrunch.com/2014/08/25/amazon-will-officially-acquire-twitch/">acquired by Amazon for USD $970 million back in 2014)</a> and <a href="https://gaming.youtube.com/">YouTube Gaming</a> dominating the market with a combined +90% market share and 343% and 197% annual growth respectively. Playing catch-up, Facebook has <a href="https://www.recode.net/2018/1/26/16934662/facebook-livestreaming-video-games-esports">attempted to seed its platform </a>by paying streamers with a few hundred followers a reported USD $10,000 per month to play exclusively on the platform.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/810/1*IPE8bn6IvVuFxRHGnGJClw.png" /><figcaption>Number of Unique Active Streamers, 2017</figcaption></figure><blockquote>Investor Takeaway: We believe Twitch &amp; YouTube will continue to benefit from strengthening network effects: more streamers → more viewers → more streamers → and so on.</blockquote><p>The explosion in eSports audiences is driving some interesting venture capital activity at the Broadcasting, Community &amp; Betting level:</p><ul><li><a href="https://www.superleague.com/">Super League Gaming </a>(raised USD $24.1 million led by <a href="https://index.co/company/NickelodeonTV/investments">Viacom’s Nickelodeon Division</a> and <a href="http://phx.corporate-ir.net/phoenix.zhtml?c=192773&amp;p=irol-irhome">Cinemark Theaters</a>) allows League of Legends, Minecraft, and Clash players to compete in movie theaters surrounded by their local gaming community.</li><li><a href="https://www.sliver.tv/about">Sliver.tv</a> (raised USD $23.2 million led by <a href="http://dh.vc/home">Danhua Capital</a> and <a href="http://www.heuristiccapital.com/">Heuristic Capital Partners</a>) broadcasts eSports content in 360 and VR format for amazingly immersive digital sports experiences.</li><li><a href="https://smash.gg/">Smash.gg</a> (raised USD $14.5 million led by <a href="http://www.sparkcapital.com/">Spark Capital</a>, <a href="http://horizonsventures.com/">Horizon Ventures</a>, <a href="https://www.accel.com/">Accel</a>, <a href="http://caffeinatedcapital.com/">Caffeinated Capital</a>, and <a href="https://lowercasecapital.com/">Lowercase Capital</a>) lets gamers share clips of epic headshots and in-game pranks.</li><li><a href="https://www.playtaunt.com/">Taunt </a>(raised USD $4.8 million led by <a href="https://www.foundrygroup.com/">Foundry Group</a>) lets eSports fans bet on the outcomes of matches.</li><li><a href="http://www.vyesports.com/">VY Esports</a> (raised USD $3.5 million led by <a href="https://www.raine.com/">Raine Ventures</a> &amp; <a href="http://courtsidevc.com/">Courtside Ventures</a> [SportsTech VC]) connects advertisers to teams and events for sponsorship opportunities.</li><li><a href="https://gamerlink.gg/">Gamerlink</a>, (raised CAD $50k from <a href="https://www.futurpreneur.ca/en/">Futurpreneur Canada</a>, a Toronto-based Accelerator) helps gamers who are looking for groups (LFG) of other players to play with across over 200 major titles.</li></ul><blockquote>Investor Takeaway: eSports represents a unique, natively omni-channel experience with a young, technically proficient audience. I expect to see increasing investment and innovation specifically within Community &amp; Betting.</blockquote><p><strong>Level 3: Hardware &amp; Accessories</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4iCNgnZGvMtRnC_vWv_NDQ.png" /><figcaption>Level 3</figcaption></figure><p><strong>Hardware </strong>in the PC gaming segment is dominated by legacy providers with products targeting the unique speed requirements and design preferences of gamers:</p><ul><li><a href="https://rog.asus.com/"><strong>ASUS</strong>’ Republic of Gamers</a></li><li><a href="https://www.amd.com/en/RX-series"><strong>AMD</strong> Radeon</a></li><li><a href="https://www.dell.com/en-ca/shop/game-ready/ab/dell-gaming"><strong>Dell</strong> Gaming</a></li><li><strong>NVIDIA</strong> just <a href="https://www.reuters.com/article/nvidia-tech/new-nvidia-gaming-chips-tap-artificial-intelligence-for-speed-idUSFWN1VB0DJ">crammed some AI </a>into a ‘gamer’-focused chip</li></ul><p>Aside from the horizontal manufacturers above, <a href="https://www.razer.com/">Razer</a> is the leading vertical brand focused entirely on the needs of gamers building complete PCs and laptops.</p><blockquote>Investor Takeaway: PC gaming hardware is the domain of legacy providers with massive capital reserves for production scale manufacturing and multi-generation research — we are unlikely to see massive disruption here from startups.</blockquote><p><strong>Accessories </strong>have long been available to augment consumer grade headphones, mice, chairs, and controllers for console and PC gamers.</p><p>One of the biggest trends in gaming is cross-platform play which allows PC gamers to play against console and mobile gamers. The problem with cross-platform play today is that PC gamers have a massive in-game advantage: an 81 input keyboard [I counted] compared to only 14 input keys on a standard console controller. This allows PC players a single-tap-per-function as compared to multi-tap-functions for console gamers, a huge advantage in split-second battles (<a href="https://www.pcgamer.com/aim-training/">not to mention the omni-directional mouse</a>). In response, third-party manufacturers are building console and mobile controllers with more input buttons to level the playing field. The leading company in this space today is <a href="https://scufgaming.com/">Scuf</a> gaming (PE-backed by <a href="http://www.chathamcapital.com/">Chatham Capital</a>) but special shout out to my <a href="https://www.ebay.com.au/itm/XBOX-Microsoft-Original-Controller-S-Madcatz-Wireless-Controller-Lot-of-2/183397513234?hash=item2ab357f812:g:URYAAOSwky1bgI5F">transparent </a><a href="http://www.madcatz.com/">Mad Catz</a> controller from the Halo 2 days.</p><blockquote>Investor Takeaway: I expect to see increasing investment in performance-based accessories for both the PC and console gaming segments. However, hardware is (still) hard and while building consumer brands around physical goods has gotten easier with social ad targeting , it has simultaneously gotten <a href="http://www.thetwentyminutevc.com/andrewdudum/">more difficult for brands to stand out</a> on platforms like Instagram. We are unlikely to see massive venture dollars invested at this tier.</blockquote><p><strong>Level 4: Services</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*jwU-Uft0HBc84n32sCJ71w.png" /><figcaption>Level 4</figcaption></figure><p>We see emerging value creation within the services layer that helps eSports competitors and their teams with the traditional front and back office functions of professional sports teams: marketing, engagement, and coordination. Within the specific context of eSports — teams leverage this software to collaborate with their teams in live competition, engage with their fans, optimize their gaming networks, and train their [head]shots.</p><p><strong>Collaboration</strong></p><p>The eSports collaboration market is segmented by intra-game communication and inter-game coordination.</p><p>One of the specialized tools that emerged to help eSports teams coordinate outside of the game is <a href="https://www.guilded.gg/">Guilded.gg</a>. Guilded functions as a team’s ERP — a centralized communications and collaboration platform for scheduling, document management, media storage (saving sweet videos), player management, and recruiting. It is already a top app for Overwatch teams with more than 10,000 teams using the service. The company raised a USD $3.2 million seed round from Initialized Capital, Susa Ventures, and FUEL Capital in September 2017.</p><p>Video game communication is dominated by <a href="https://discordapp.com/">Discord</a>, a free chat and voice communication app custom-built for gamers, with a premium ‘Nitro’ tier available for USD $4.99/month. <a href="https://player.fm/series/recode-media-with-peter-kafka/discord-ceo-jason-citron">CEO Jason Citron</a>’s <a href="https://soundcloud.com/a16z/earned-secrets-ben-horowitz-interns-2018">earned secret</a> was traditional voice and chat applications that interrupt gameplay don’t work for gamers (imagine being on a killstreak and having a call pop up in your screen!!). Discord is <a href="https://www.gamespot.com/forums/pc-mac-linux-society-1000004/why-use-discord-33421411/">generally considered </a>to have low-bandwidth, high-quality VoIP audio and video that can allow users to collaborate outside of the game vs. in game communication channels offered in major titles/platforms where it can be difficult to connect players who are offline. In 2018, the company reached 45 million registered users, with 10 million daily active users. In April 2018, Discord reached a post-money valuation of USD $775 million and has raised a total of USD $152 million from leading Silicon Valley investors including <a href="https://www.ivp.com/">Institutional Venture Partners</a>, <a href="https://www.indexventures.com/">Index Ventures</a>, <a href="http://www.sparkcapital.com/">Spark Capital</a>, <a href="https://www.greylock.com/">Greylock Partners</a>, and <a href="http://www.benchmark.com/">Benchmark</a>.</p><p>Also competing in the video-game communication services arena is <a href="https://www.teamspeak.com/en/">TeamSpeak</a>, a VoIP communication service marketed at gamers but also used by NASA and Boeing. The service touts complete user control, from basic UI layout to server configurations. According to data from Crunchbase and LinkedIn, the company has under 50 employees, was founded in 2001, and has not raised venture financing.</p><blockquote>Investor takeaway: Gaming communication platforms like Discord have become social networks — disintermediating PlayStation Plus and Xbox Live which are inherently not cross-platform and struggle as independent mobile experiences. Discord represents the next important social experience channels for Generation Z gamers.</blockquote><p><strong>Engagement</strong></p><p>Similar to professional teams, eSports teams need to engage both audiences and advertisers</p><p><a href="https://www.curse.com/">Curse</a>, a US company acquired by Amazon’s Twitch in 2016 focuses on bridging the gap between advertisers and its 20.8 million unique monthly site visitors and global events advertising platform.</p><blockquote>Special shout out to Bezos for quietly building a vertically integrated gaming empire starting back in 2014:</blockquote><blockquote><a href="https://www.businessinsider.com/amazon-buys-double-helix-games-2014-2">Double Helix Studios</a> → <a href="https://www.businessinsider.com/amazon-buys-twitch-2014-8">Twitch</a> → <a href="https://www.curse.com/">Curse </a>→ ???</blockquote><blockquote>all running on 😏 AWS</blockquote><p><a href="https://www.curse.com/">Curse </a>raised USD $71 million from <a href="https://www.riotgames.com/en">Riot Games</a> (creator of League of Legends), <a href="https://www.ggvc.com/">GGV Capital</a>, and <a href="https://uncorkcapital.com/">Uncork Capital</a>. In 2016, the company transitioned from a World of Warcraft modification (mod) repository to voice and chat platform that integrates with viewing platforms like Twitch and YouTube for one-click content management.</p><p><a href="https://www.fanai.io/">Fan.ai</a> uses artificial intelligence to help eSports teams identify, segment, and engage their audiences to maximize sponsorship and advertising revenues. The company boasts major global eSports teams as customers, including <a href="http://cloud9.gg/">Cloud9</a>, <a href="https://www.immortals.gg/">Immortals</a>, and <a href="https://discordapp.com/invite/rKjv4P8">Excelsior </a>as well as eSport festival <a href="https://dreamhack.com/">Dreamhack</a>. Fan.ai was founded in 2016 in Santa Monica and has raised USD $10 million from <a href="http://courtsidevc.com/">Courtside Ventures</a>, <a href="http://www.chinarockcapital.com/">ChinaRock Capital Management</a>, <a href="http://www.bitkraft.net/">Bitkraft Esports Ventures</a>, <a href="https://www.prnewswire.com/news-releases/veteran-sports-executives-launch-new-agency-focused-on-global-growth-sports-300357363.html">Catalyst Sports</a>, and others.</p><blockquote>Investor Takeaway: I expect to see additional investment and innovation at this layer as teams fight to own a greater share of their audience’s attention and wallets, away from major viewing platforms Twitch and YouTube Gaming. This is analogous to Ben Thompson’s <a href="https://stratechery.com/2015/aggregation-theory/">Aggregation Theory</a> in which value accrues disproportionately to the platforms which aggregate content (Twitch would be Facebook in this analogy) vs. those groups that create content (gamers would be the content publishers).</blockquote><p><strong>Optimization</strong></p><p>There are a number of network optimization tools designed to improve the speed and quality of internet connection for gamers, the most prominent of which are Haste and WTFast.</p><ul><li><a href="https://haste.net/">Haste </a>(USD $4.4 million from <a href="http://blhventures.com/">BLH Ventures</a> and angels) has built a specialized gaming network (<a href="https://haste.net/haste-technology/">analogous to a VPN</a>) to optimize the packet delivery from gamer to gaming server by routing traffic through protected hubs while continuously monitoring network performance.</li><li><a href="https://www.wtfast.com/">WTFast </a>(USD $0.5 million from <a href="http://www.bitkraft.net/">Bitkraft Esports Ventures</a>, <a href="https://valhallaangels.com/">Valhalla Angels</a>, and others) also a offers “lag-free” gaming experience and boasts major corporates as partners, including Amazon, ASUS, GameStop, and Linksys.</li></ul><blockquote>Investor Takeaway: While I am tempted to write off these services as network speeds continue their march towards light-speed with FTTH/5G — lag is still a real problem, even for professional gamers — likely due to a correlated increase in the size and complexity of modern games. For example, lag killed professional gamers who were competing in a July 2018 Fortnite tournament for USD $250,000 (<a href="https://www.youtube.com/watch?v=Sgu6PoCvZy4">video has NSFW language</a>).</blockquote><p><strong>Training</strong></p><p>An emerging area of eSports services are analytics engines that capture game-play data and produce insights for teams and managers to improve their performance.</p><p><a href="https://pursuit.gg/">Pursuit</a>.gg (disclaimer — OMERS Ventures is an investor) offers users automated benchmarking of key game statistics relative to other players in post-game reports. Today, the company is focused on providing insights for <a href="https://playoverwatch.com/en-us/">Overwatch </a>and is used by eSports teams including Team Canada, the Philadelphia Fusion, and the Angry Titans. The company has raised USD $4.7 million from <a href="http://omersventures.com/">OMERS Ventures</a>, <a href="https://evp.vc/">Extreme Venture Partners</a>, <a href="https://foundationcapital.com/">Foundation Capital</a>, <a href="https://www.scalevp.com/">ScaleUP Ventures</a>, and others.</p><p><a href="https://visor.gg/">Visor.gg</a> is another Overwatch analytics engine that offers comprehensive post-game insights and detailed match breakdown for teams and individual gamers. The company was founded in 2017, graduated from Y Combinator’s Winter 2018 class, and has gone on to raise USD $6.6 million in venture funding from <a href="https://www.accel.com/">Accel</a>, <a href="https://nextgenvp.com/">NextGen Venture Partners</a>, and <a href="http://www.mcvcpartners.vc/">MCVC Partners</a>.</p><p><a href="https://plays.tv/">Plays.tv</a> is a lightweight tool for PC gamers that records gameplay and allows players to drop bookmarks at key moments — like a death or kill — to review afterwards and assess their strategy. The company does not currently advertise automated analytics or insights — but with USD $15 million in venture financing raised from <a href="https://shastaventures.com/">Shasta Venture</a>, <a href="https://www.49ers.com/">The San Francisco 49ers</a>, <a href="https://www.accel.com/">Accel</a>, and <a href="https://foundersfund.com/">Founders Fund</a> — I would bet this is on their roadmap. Currently, the website boasts players from leading global teams including Cloud9 and Fnatic.</p><p><a href="https://www.sap.com/">SAP</a> (disclaimer — my previous employer) has partnered with <a href="https://www.teamliquidpro.com/">Team Liquid</a> to provide in-game and post-game analytics to players and coaches across a number of titles. SAP has a <a href="https://www.asug.com/news/saps-new-game-plan-combining-big-data-analytics-and-big-time-sports">history</a> of providing sports analytics and management tools to traditional organizations and has set its sights on replicating these offerings for digital sports.</p><blockquote>Investor Takeaway: I believe there is an incredible opportunity to ingest and analyze video game data — which is inherently easier to map than physical sports — to optimize player performance. If we play out the increasing professionalization of video games — training tools should automate away the much hyped <a href="https://www.wsj.com/articles/ready-aim-hire-a-fortnite-coach-parents-enlist-videogame-tutors-for-their-children-1533046708">Fortnite tutor</a>.</blockquote><p><strong>Level 5: Superstars &amp; Teams</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*P3aeMgpc0RlYIkwjJtI17Q.png" /><figcaption>Level 5</figcaption></figure><p>The current trend to note at this tier is the transition of video game competition from one-off tournaments to leagues that increasingly resemble traditional sports. While winnings from eSports tournaments can rival any traditional sports competition (see below) the next stage of maturation is more regular professional match play.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/750/0*oN8zuVYOBzw2gvRy.jpg" /></figure><p><strong>Teams</strong></p><p>Similar to traditional sports organizations, eSports teams can either be singularly focused on one gaming title or compete in multiple leagues — known as <em>endemic </em>eSports teams. For a traditional sports example, the <a href="https://mlse.com/teams/">Maple Leaf Sports &amp; Entertainment</a> group owns the Toronto Maple Leafs (NHL), Toronto Raptors (NBA), Toronto Football Club (MLS), Toronto Argonauts (CFL), and affiliated farm teams.</p><p>Top endemic eSports teams like Team Liquid and Evil Geniuses have won over USD $20 million each in prize money alone with teams competing in many different games. For an eSports example, Team Liquid has teams in the following 14 games:</p><ul><li><a href="https://starcraft2.com/en-us/">Starcraft II</a></li><li><a href="https://na.leagueoflegends.com/en/">League of Legends</a></li><li><a href="https://playhearthstone.com/en-us/">Hearthstone</a></li><li><a href="http://blog.counter-strike.net/">Counter Strike; Global Offensive (CS:GO)</a></li><li><a href="http://www.dota2.com/international/overview/">DotA2</a></li><li><a href="https://heroesofthestorm.com/en-us/">Heros of the Storm</a></li><li><a href="https://www.youtube.com/watch?v=dQw4w9WgXcQ">Super Smash Brothers</a> (← sorry had to)</li><li><a href="https://streetfighter.com/">Street Fighter</a></li><li><a href="https://www.easports.com/fifa">FIFA</a></li><li><a href="https://store.steampowered.com/app/578080/agecheck">Player Unknown Battlegrounds (PUBG)</a></li><li><a href="https://quake.bethesda.net/en">Quake</a></li><li><a href="https://rainbow6.ubisoft.com/siege/en-ca/home/">Rainbow Six</a></li><li><a href="https://clashroyale.com/">Clash Royale</a></li><li><a href="https://www.epicgames.com/fortnite/en-US/buy-now/battle-royale">Fortnite</a></li></ul><p>As professional gaming leagues expand — we have seen an explosion of interest from technology investors and traditional sports organizations who want to own teams in key eSports leagues. The current hype is over the expansion of the Overwatch League with investors including Comcast and Robert Kraft (founder of Kraft foods and owner of the NFL’s New England Patriots and the MLS’ New England Revolution) spending up to a reported USD <a href="http://www.espn.com/esports/story/_/id/23464637/overwatch-league-expansion-slots-expected-30-60-million-sources-say">$60 million </a>for the rights to own their local franchise.</p><p>The venture world was introduced to this conglomerate team concept by <a href="http://cloud9.gg/">Cloud9</a>, which raised USD $25 million from <a href="https://foundersfund.com/team/peter-thiel/">Peter Thiel</a>’s <a href="https://foundersfund.com/">Founders Fund</a> and a mix of well known angel investors including <a href="https://en.wikipedia.org/wiki/Alexis_Ohanian">Alexis Ohanian</a> founder of Reddit &amp; socially progressive celebrity husband of <a href="https://foto.gettyimages.com/sports/tennis/alexis-ohanian-serena-williams-biggest-fan/">Serena Williams</a>.</p><blockquote>Investor Takeaway: I believe there will be incredible opportunities for investors to participate in eSports, while using an endemic, conglomerate structure to diversify away from the popularity of any one video game ‘hit’.</blockquote><p><strong>Players</strong></p><p>The key thing for investors to understand is the power and monetization strategies of eSports stars is incredibly similar to traditional sports stars, with one major difference. Both eSports and traditional sports players get paid by teams, tournaments, and advertising sponsors. But eSports players can generate a significant percentage of their income from donations and prime subscribers from Twitch (<a href="https://theoutline.com/post/2571/no-one-makes-a-living-on-patreon">what Pateron tried to do</a>). Donations or “donos” involve individual viewers gifting small amounts of cash (or <a href="https://www.hotnewhiphop.com/drake-donates-s5k-to-ninja-after-clutch-fortnite-victory-news.47571.html">$5k if you’re Drake</a>) to cheer on their favorite players. On Twitch, viewers can also sign up to be <a href="https://www.twitch.tv/prime">prime</a> subscribers to their favorite players to get special emojis and perks. Players keep half of the $5.00/month prime subscriber fee and Twitch keeps the other half.</p><p>Those numbers can add up quickly for the world’s top streamers like Fortnite’s <a href="https://www.twitch.tv/ninja">Ninja</a>, who has ~150,000 prime subscribers which is worth over USD $500,000 per month. This income comes before his other sponsorship deals and tournament winnings.</p><blockquote>Investor Takeaway: unless we see a <a href="https://fantex.com/">Fantex</a> clone, we are unlikely to see major investment opportunities for technology investors at the Player tier.</blockquote><p><strong>Leagues</strong></p><p>The <a href="https://overwatchleague.com/en-us/">Overwatch League</a> is the first eSports initiative to follow the traditional sports team model with franchises for major cities around the world, live events, and salaried athletes. Along with all the revenue streams of traditional sports leagues — ticket sales, media rights, licensing, ancillaries, etc. — there are unique opportunities to monetize virtual merchandise. For example, fans will be able to buy a “skin” so that when they’re playing Overwatch at home, their hero will be wearing the jersey of their city’s team.</p><p>The real reason eSports leagues are receiving attention and investment from traditional sports organizations is because of the stark contrast between the average age of their viewers, shown below.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*8n2XtBCPsNXwzn84KhcPPA.png" /><figcaption>Average Age of Viewer, 2016</figcaption></figure><p>eSports viewers are <strong><em>3x younger </em></strong>than PGA Tour, LPGA, and Horse Racing viewers and represent the next audience marketers and content providers will need to engage and cultivate.</p><p><strong>Level 6: Games</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6FKU8jK9LDA9AsRH52IOXg.png" /><figcaption>Level 6</figcaption></figure><p>Yes — video games themselves can be a hits driven business.</p><p>The 10 titles in the framework above have sold more than 600 million copies (with a special shout out to Fortnite) led by Tetris, which has sold 170 million copies since it was released in June 1984. Similar to how the movie industry has shifted towards a focus on <a href="http://www.latimes.com/entertainment/movies/la-ca-mn-25-most-powerful-franchises-20160524-snap-story.html">mega-franchises </a>— those multi-generational video game titles like Mario, Pokemon, Call of Duty, Grand Theft Auto, etc. have predictably massive consumption, while most other games follow a more polarized outcome distribution (known as ‘hits’).</p><p>Generally, the market is dominated by first-person shooters (FPS) and third-person shooters (TPS) with sports and role playing games coming in as runner up genres.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/554/1*hXl0qjBAtJzV86OFjQHO7Q.png" /><figcaption>Genre breakdown of video game sales in the United States, 2017</figcaption></figure><p>This would not be a VC post without discussing the cloud ☁️ — which has permeated every industry as the preferred method of software distribution and consumption — including video games. The trend for investors to understand is that the traditional model of video game consumption has shifted from a single, upfront purchase of a physical disc for about USD~$70 to the current model of freemium video games with in-game purchases of downloadable content (DLC).</p><p>DLC can include things like additional maps or areas within maps; more powerful weapons or items; player experience upgrades; new or past favorite characters and skins; and hardcore game level modes.</p><p>An example of DLC gone wrong is with EA’s Star Wars Battlefront II — in which players could either buy key characters Luke Skywalker and Darth Vader for around $20 or play 80 hours (way too much) to unlock the characters. After complaints surfaced online about the time and cost, <a href="https://www.reddit.com/r/StarWarsBattlefront/comments/7cff0b/seriously_i_paid_80_to_have_vader_locked/dppum98/">EA responded</a> that its intent was to “provide players with a sense of pride and accomplishment”. This comment by EA has the dubious distinction of being <a href="https://www.reddit.com/r/ListOfComments/wiki/downvoted">the most downvoted comment ever on Reddit</a> (683,000 downvotes as at September 2018).</p><p>Fortnite is a study in DLC done right. The game itself is free — but players can pay to download special characters, skins, and game modes. The Epic Games title is reported to have earned over USD $1 billion over LTM May 2018 with USD $318 million coming in the last month alone.</p><blockquote>Investor Takeaway: the changing consumption model for video games, while an important industry trend, is unlikely to directly affect early-stage technology investors unless you are investing in game developers (below).</blockquote><p><strong>Level 7: Game Developers</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*xE9Uvm6YPb4uI7xLfmUfxw.png" /><figcaption>Level 7</figcaption></figure><p>Video game developers range from large public entities like <a href="https://finance.yahoo.com/quote/ATVI/">Activision Blizzard</a>, <a href="https://finance.yahoo.com/quote/EA/">Electronic Arts</a>, <a href="https://finance.yahoo.com/quote/UBI.PA?p=UBI.PA&amp;.tsrc=fin-srch">Ubisoft</a>, <a href="https://finance.yahoo.com/quote/TCEHY?p=TCEHY&amp;.tsrc=fin-srch">Tencent </a>and <a href="https://finance.yahoo.com/quote/NTDOY?p=NTDOY&amp;.tsrc=fin-srch">Nintendo</a>; large privately held studios <a href="https://www.epicgames.com/site/en-US/home">Epic Games</a> (Fortnite); and smaller indie studios like Toronto’s <a href="https://www.bigvikinggames.com/">Big Viking Games</a>. The investing profile of these studios mirrors the polarized distribution of outcomes for games — if a studio makes a ‘hit’ they can have a spectacular outcome.</p><blockquote>Investor Takeaway: investing in studios hoping for a USD <a href="https://techcrunch.com/2016/02/23/activision-blizzard-closes-its-5-9b-acquisition-of-king-makers-of-candy-crush/">$5.9 billion acquisition</a> like King Mobile is a ‘hits’ bet — wager on friends.</blockquote><p><strong>Level 8: Game Engines</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*avgwNI9aNtdk3wKJOMl2dQ.png" /><figcaption>Level 8</figcaption></figure><p>A game engine is a software development environment used to build video games. Engines have evolved significantly as PC and console hardware power has ramped up over time to render increasingly complex worlds (great overview <a href="https://prezi.com/w56f8xawwcyg/the-history-of-game-engines/">here</a>).</p><p>The gaming engine market is highly consolidated. Top engines include PE-backed <a href="https://unity3d.com/">Unity</a> which raised USD $400 million from <a href="https://www.silverlake.com/">Silver Lake</a>, <a href="https://dfj.com/portfolio/index.php?stage_keyword=Growth">DFJ Growth</a>, <a href="https://www.sequoiacap.com/">Sequoia Capital</a>, and others, which owns an estimated <a href="https://instabug.com/blog/game-engines/">45% of the gaming market</a>, followed by Epic Game’s <a href="https://www.unrealengine.com/en-US/what-is-unreal-engine-4">Unreal Engine </a>which owns approximately 17%.</p><blockquote>Investor Takeaway: given the massive capital requirements and extensive research &amp; development required to build a modern gaming engine — I don’t expect to see much opportunity for early-stage venture investors here.</blockquote><p><strong>Level 9: Platforms</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5BuZW5Yj2zVv_EkJDpc1Qw.png" /><figcaption>Level 9</figcaption></figure><p>Distribution mechanisms for video games can exist as extensions of the underlying gaming platform or decoupled marketplaces that exist separately. Coupled distribution networks are more common in console gaming, as Xbox, PlayStation, and Nintendo all operate their own stores via their online networks, and mobile gaming in which apps are distributed by the Apple App Store or the Google Play Store on those respective platforms. PC gaming is an example of a decoupled gaming distribution in which users can access separate services like Steam, itch.io, and others for many different gaming titles, or go directly to game developers’ websites to download their specific content.</p><p><a href="https://www.valvesoftware.com/en/">Valve</a>, the privately-held company behind <a href="https://steamcommunity.com/market/">Steam</a>, the <a href="https://store.steampowered.com/sale/steam_machines">Steam-Machine console</a>, and hit games <a href="https://en.wikipedia.org/wiki/Half-Life_(video_game)">Half-Life</a>, <a href="http://left4dead.wikia.com/wiki/Left_4_Dead_Wiki">Left 4 Dead</a>, and <a href="https://en.wikipedia.org/wiki/Dota_2">Dota 2</a> amongst others, is one of the most interesting private companies in the United States. Originally started in 1996 as a game developer by two former Microsoft employees, the company has expanded beyond game development to build Steam, an online PC game marketplace that sells games to its 125 million active users (6 million of which are daily active users). In 2011, the company was reported as having the highest profit per employee of any privately held company in the United States. In January of 2018, the company was subject of <a href="https://www.polygon.com/2018/1/31/16955204/microsoft-valve-acquisition-xbox-steam">acquisition rumors</a> by Microsoft, who would be looking to purchase rights to Xbox specific games as well as combine the PC game marketplace with their existing offerings.</p><blockquote>Investor Takeaway: although major titles like <a href="https://bgr.com/2018/08/06/fortnite-for-android-download-no-google-play-security-risks/">Fortnite have been able to circumvent platform distribution channels</a> to avoid paying the 30% pound of flesh demanded by Apple, Google and alike — I believe it is unlikely to see a further decoupling of distribution channels from core console and mobile platforms as the key distribution channel. In PC — distribution will remain fragmented and continue to be owned largely by Steam (estimated 70% of all online video game sales).</blockquote><p><strong>Level 10: Platforms</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*9LFDRFoQ67Vygf0jtR5OCw.png" /><figcaption>Level 10</figcaption></figure><p>Broadly, we can segment gaming Platforms into PC, console, handheld, mobile, and VR. Generally, we see the incumbents on a cycle of incremental innovation updating PC, console, and mobile platforms — the domains of large public companies like Apple, Google, Microsoft, Sony, and Nintendo. However, as new technology platforms emerge we see the unique opportunity for new players to take a leading position — with the most recent example being Virtual Reality.</p><p>Within VR, <a href="https://www.oculus.com/">Oculus</a> is a rare example of a small team that raised just USD $91 million from venture investors to build a meaningful product for an emerging technology platform, innovating faster than industry incumbents. The Oculus team was taken out by <a href="https://www.forbes.com/sites/briansolomon/2014/03/25/facebook-buys-oculus-virtual-reality-gaming-startup-for-2-billion/">Facebook for USD $2 billion</a> in 2014. Of course, that acquisition was about much more than gaming, as VR represents a future paradigm for virtual human interaction, but this thesis for emerging technology platforms extends into other consumer realms of social, entertainment, media, and alike.</p><p><strong>Looking Ahead</strong></p><p>Broadly, we see the most interesting investment opportunity at the highest tiers of the framework, with innovation percolating closer to the growing number of video games players and audiences. I believe we will see increasing venture dollars flowing specifically towards:</p><p>Level 2 — Broadcasting, Community, and Betting;</p><p>Level 4 — Services</p><p>Level 5 — Superstars &amp; Teams</p><p>Game studios will produce evergreen investment opportunities as cultural forces shape new game phenomenons, like the current <a href="https://steamcommunity.com/discussions/forum/12/1700542968203521496/">battle royale</a> hype. Like I said, a portion of the industry will always be a ‘hits’ business.</p><p><strong>Summary</strong></p><p>I hope you have walked away from this article with a better understanding of the existing incumbents and high-trajectory start-ups in the eSports and video game world.</p><p>I look forward to connecting with those companies I have missed and investors who share a different perspective.</p><p>.</p><p>.</p><p>.</p><p>GG everyone!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f4c0da80f1e0" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>